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1 ABBREVIATIONS 
Acetyl-CoA Acetyl coenzyme A 
ADP Adenosine diphosphate 
adPEO Autosomal dominant PEO 
AID Accessory interacting determinant (subdomain in POLG1) 
AMP Adenosine monophosphate 
ANT1 Adenine nucleotide translocator 
APU Average processed unit 
ARJPD Autosomal recessive juvenile Parkinson’s disease 
arPEO Autosomal recessive PEO 
ARSACS Autosomal recessive spastic ataxia of Charlevoix-Saguenay 
ATP Adenosine triphosphate 
BP Base pair 
CI Respiratory chain complex I 
CII Respiratory chain complex II 
CIII Respiratory chain complex III 
CIV Respiratory chain complex IV 
COX Cytochrome c oxidase 
DNA Deoxyribonucleic acid 
DNM1L Dynamin-1-like protein 
dNTP Deoxyribonucleotide 
dRP 5’-deoxyribose phosphate 
dsDNA Double stranded DNA 
ER Endoplasmic reticulum 
ETC Electron transport chain 
IOSCA Infantile-onset spinocerebellar ataxia 
IP Intrinsic processivity (subdomain in POLG1) 
LRRK2 Leucine-rich repeat kinase 2 
LSP Light strand promoter 
MAM Mitochondria associated endoplasmic reticulum membrane 
MELAS Mitochondrial encephalomyopathy, lactic acidosis, and stroke-
like episodes 
MFN1 Mitofusin 1 
MFN2  Mitofusin 2 
Mip1 Yeast mitochondrial DNA polymerase 
MIRAS Mitochondrial recessive ataxia syndrome 
MNGIE Mitochondrial neurogastrointestinal encephalopathy 
MRI Magnetic resonance imaging 
mtDNA Mitochondrial DNA 
MPTP 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine 
mtSSB Mitochondrial single-stranded DNA binding protein 
NAD+ Nicotinamide adenine dinucleotide 
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nDNA nuclear DNA 
nt Nucleotide 
OPA1 Optic atrophy 1 
OXPHOS Oxidative phosphorylation 
PD Parkinson’s disease 
PEO Progressive external ophthalmoplegia 
Pi  Inorganic phosphate 
PINK1 PTEN-induced putative kinase protein 1 
POLG Mitochondrial DNA polymerase / DNA polymerase gamma 
POLG1 Mitochondrial DNA polymerase, catalytic subunit 
POLG1-PD PEO with parkinsonism, caused by POLG1 mutations 
POLG2 Mitochondrial DNA polymerase, accessory subunit 
POLRMT Mitochondrial RNA polymerase 
ptDNA primer-template DNA 
RNA Ribonucleic acid 
RNS Reactive nitrogen species 
ROS Reactive oxygen species 
RRF Ragged red fibers 
RRM2B Ribonuclease reductase 2 B 
SANDO Sensory ataxic neuropathy, dysarthria and ophthalmoparesis 
Sirt1 Sirtuin1 
SN Substantia nigra 
ssDNA Single stranded DNA 
T7 GP4 T7 gene product 4 primase-helicase 
TCA Tricarboxylic acid cycle 
TFAM Transcription factor A, mitochondrial 
TFB2M Transcription factor B2, mitochondrial 
TK2 Thymidine kinase 2 
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2 ABSTRACT 
Mitochondrial dysfunction is a common cause of hereditary 
neurodegenerative diseases, such as Parkinson’s disease and inherited ataxia 
syndromes. Frequent causes of mitochondrial dysfunction are mutations in 
mitochondrial  DNA  (mtDNA)  or  mutations  in  the  genes  encoding  the  
mtDNA replication machinery. The minimal mtDNA replication machine 
consists of mitochondrial DNA polymerase, named DNA polymerase gamma 
(POLG), TWINKLE helicase and mitochondrial single-stranded DNA binding 
protein (mtSSB). Mutations in the gene POLG1, which encodes the catalytic 
subunit of POLG, cause a heterogeneous group of disorders with varying 
clinical phenotypes, such as mitochondrial recessive ataxia syndrome 
(MIRAS), progressive external ophthalmoplegia (PEO) and Alpers’ 
syndrome. MIRAS is the most common inherited ataxia in Finland and a 
frequent form of inherited ataxia in Norway and Belgium. Sequence variants 
in POLG1 also alter the risk of developing idiopathic Parkinson’s disease. The 
cause of variability in the clinical manifestations is unknown. 
 
Our results indicate that respiratory chain complex I (CI) deficiency does 
not explain parkinsonism in POLG1-PD patients and that mesencephalic 
alterations are a common feature in patients with dysfunctional mtDNA 
replication machinery. We have also elucidated the pathogenic mechanisms 
of  MIRAS,  from  the  molecular  alteration  of  POLG1  function  to  the  
neuropathological changes and clinical phenotype, and thus our results help 
to understand the varying clinical manifestations associated with POLG1 
mutations.  In  addition,  we  have  produced  a  classification  of  POLG1 
mutations, which could be useful in the evaluation of the potential 
pathogenicity of new POLG1 mutations.  
 
In this thesis, we studied the clinical picture of MIRAS. The high carrier 
frequency of the MIRAS disease allele in Finland, Norway and Belgium may 
lead to multiple introductions of the disease allele and some MIRAS cases to 
be mistakenly recognised as dominantly inherited, thereby leading to the 
exclusion  of  MIRAS  as  the  diagnosis.  We  described  a  family  in  which  both  
mother and son had MIRAS-like disease. We found that the father was a 
carrier of the MIRAS disease allele. Thus, MIRAS should not be ruled out by 
an apparently dominant mode of inheritance in countries with high carrier 
frequency of the disease allele. 
 
Patients with PEO caused by POLG1 mutations have variable clinical 
manifestations, including premature menopause and parkinsonism (POLG1-
PD). The cause of this variability is unknown. Also, the variability in clinical 
features is more evident in POLG1 diseases: diseases caused by malfunction 
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of other mitochondrial DNA replication proteins cause usually clear clinical 
phenotypes, with no such variation. We studied the pathogenic changes 
leading  to  parkinsonism  by  performing  a  neuropathological  examination  of  
the mesencephalon of two PEO patients with parkinsonism and by 
comparing the changes to patients with MIRAS, infantile-onset 
spinocerebellar ataxia (IOSCA) or PEO caused by mutations in C10ORF2, the 
gene encoding TWINKLE. POLG1-PD patients had an almost complete loss 
of neurons in substantia nigra (SN) whereas MIRAS, IOSCA and Twinkle 
PEO patients had also mild to moderate neuronal loss in the SN. POLG1-PD 
patients had also moderate loss of neurons in the oculomotor nucleus. CI 
activity  was  clearly  reduced  in  the  SN  of  all  patients.  The  parkinsonism  in  
POLG1-PD patients is in our view secondary to the drastic neuron loss in the 
mesencephalon and the lack of CI activity is a general feature of diseases 
caused by dysfunctional mitochondrial DNA replication and it does not 
correlate with parkinsonism, age or phenotype of the patients. 
 
We studied the biochemical background underlying MIRAS and found 
that p. Trp748Ser POLG1 does not exhibit a biochemical phenotype in DNA 
polymerase function. Our findings challenge previously published results and 
their implications. We biochemically characterized recombinant POLG1, with 
the MIRAS causing amino acid change: p.Trp748Ser. The mutant POLG1 did 
not have any decrease in DNA polymerase activity on various primer-
template DNAs or in the subunit interaction with the accessory subunit. 
There  was  a  minor  decrease  in  the  DNA  binding  capability  of  the  
p.Trp748Ser POLG1, but this did not alter the overall efficiency of the 
enzyme as measured in the processivity.  
 
We examined the distribution of Alpers’ syndrome causing mutations on 
the protein structure of POLG1. We found that the mutations can be divided 
into five distinct groups, each with a different biochemical profile. Our 
findings were supported by the published biochemical characterizations of 
various mutant POLG1 enzymes. Based on the structural data, we predict 
that the p.Trp748Ser amino acid change affects the interaction with mtSSB 
and not intrinsic DNA polymerase activity or DNA binding of POLG1, which 
could explain the results from biochemical characterization. 
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3 INTRODUCTION 
One essential challenge of life is reproduction. This requires that we grow 
and survive the daily obstacles. A major obstacle revolves around food, or 
more specifically, energy, which we need in order to survive. Humans have 
evolved to efficiently use various sources of stored energy: plants, which have 
stored energy produced by the sun and meat, into which energy stored by 
plants is processed. We can divide the various energy stores into 
carbohydrates, proteins and fatty acids.  The elegant process that breaks 
down these energy stores efficiently into adenosine triphosphate, the 
common unit of energy used by our cells, revolves around mitochondria. 
Mitochondria are cellular organelles that are essential for our energy 
metabolism.  They  have  their  own  genome,  which  has  given  evolution  the  
possibility to experiment with more complex systems that use energy more 
efficiently and ultimately produce higher organisms, such as humans. 
 
The proper function of mitochondria is important for the well-being of a 
cell and in the end, the whole organism. Dysfunctional mitochondrial can 
lead to disease. Mitochondrial diseases are a heterogeneous group of 
diseases, ranging from metabolic diseases such as diabetes mellitus to 
neurodegenerative disorders such as Parkinson’s disease. Neurodegenerative 
phenotypes produce the most dramatic clinical manifestations and 
devastating consequences for patients. Our brain continuously requires 
enormous  amounts  of  energy  and  even  a  small  disruption  in  this  can  cause  
neuronal death, which after a certain threshold may lead to disease. Every 
neuron type has its own characteristics and energy requirements, whereas 
every disorder challenges different parts of the nervous system. These 
features at least in part contribute to the great heterogeneity of 
mitochondrial disorders. 
 
Mitochondrial diseases are diseases of energy metabolism. Mitochondrial 
DNA  encodes  the  most  conserved  core  components  of  the  oxidative  
phosphorylation enzyme complexes required for efficient energy metabolism 
and disorders of mitochondrial DNA or its replication disrupt this elegant 
process. In this thesis, we have studied the malfunction of mitochondrial 
DNA replication, caused by mutations in the mitochondrial DNA polymerase. 
Even among the various clinical manifestations caused by mitochondrial 
disease,  malfunction  of  mitochondrial  DNA  polymerase  leads  to  an  even  
more diverse set of clinical manifestations. 
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4 REVIEW OF THE LITERATURE 
4.1 THE EVOLUTIONARY ORIGINS OF MITOCHONDRIA 
The Endosymbiotic Theory is the most widely accepted theory for the origin 
of mitochondria and it hypothesises that mitochondria evolved from a single 
event in which an alpha-protobacterium was introduced into a proto-
eukaryotic cell, possibly the same event as when eukaryotes themselves 
evolved (Lane and Martin, 2010; Martin and Muller, 1998). Working as the 
power plant of the cell, it most likely allowed eukaryotes to evolve further and 
evolution to experiment with a far larger genome as was previously possible 
(Lane and Martin, 2010). Since the inception of eukaryotes and mitochondria 
their symbiosis has remained the same, but the appearance of participants 
has  taken  many  forms:  a  wide  array  of  different  eukaryotes  exists,  from  
simple baker’s yeast Saccharomyces cerevisiae to primates such as humans. 
Also, mitochondria are not equal in appearance as their size, organization 
and genome vary (Anderson et al., 1981; Palmer et al., 1992).  
 
4.2 MITOCHONDRIA AS A MEMBER OF THE CELL 
Cell organelles do not function alone or without context. Most of the proteins 
mitochondria require to function are encoded by nuclear genes. 
Furthermore, there seems not to be a population of disconnected 
mitochondria  in  most  cells  but  rather   a  mitochondrial  network  which  
encompasses the whole cell (Lewis and Lewis, 1914; Palade, 1953). This 
network is dynamic and is constantly changing its shape and composition. 
Again, this requires help from other intracellular organelles, namely the 
endoplasmic reticulum or more specifically, mitochondrial associated 
endoplasmic reticulum membrane (MAM). 
 
MAMs function as contact sites between mitochondria and endoplasmic 
reticulum and they seem to be more common than previously thought 
(Mannella  et  al.,  1998;  Rizzuto  et  al.,  1998).  They  help  in  direct  transfer  of  
lipids  between  mitochondria  and  endoplasmic  reticulum,  Ca2+ influx, 
apoptosis and mark the sites of mitochondrial division (de Brito and 
Scorrano, 2008; Friedman et al., 2011; Gaigg et al., 1995; Garcia-Perez et al., 
2008; Simmen et al., 2005). The MAM is held together with the help of 
protein  tethering  complexes,  of  which  mitofusin  2  (MFN2)  is  the  major  
component (Garcia-Perez et al., 2011). 
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4.3 MITOCHONDRIAL NETWORK 
No strict definition of a mitochondrial network exists, but every 
mitochondrion can be considered to be a part of the same network within one 
cell. The constant flux in fission and fusion of mitochondria is mediated by 
mitofusin I, II and optic atrophy I proteins (MFN1, MFN2 and OPA1, 
respectively)  in  fusion  and  dynamin  1-like  protein  (DNM1L)  in  fission  
(Figure 1) (Cipolat et al., 2004; Smirnova et al., 2001). MFN1 and MFN2 are 
homologues of yeast Fzo1p, which coordinate the fusion of the mitochondrial 
membranes whereas OPA1 regulates this interaction via MFN1. The 
dysfunction of fusion or fission results in highly abnormal mitochondria, 
especially in post-mitotic tissues such as neurons: loss of fission in neuronal 
specific DNM1L knock-out mice decreases the amount of neurites and leads 
to dysfunctional synapse formation, whereas a decrease in fusion results in 
mtDNA loss, mitochondrial motility defects and an increase in reactive 
oxygen  species  (ROS)  production  (Chen  et  al.,  2003;  Ishihara  et  al.,  2009;  
Parone et al., 2008). Instead of placing the burden of environmental 
stressors  on  individual  mitochondria,  fusion  and  fission  seem  to  divide  the  
burden  to  the  whole  network  (Chen  et  al.,  2010).  The  clinical  phenotypes  
caused by the dysfunction of fusion by mutations in MFN2 lead to Charcot-
Marie Tooth disease 2A, a disease characterized by onset in early adulthood, 
neuropathy and peripheral muscle atrophy (Zuchner et al., 2004). Mutations 
in OPA1 lead to dominant optic atrophy, which causes optic neuropathy and 
ultimately distortion of vision (Alexander et al., 2000; Delettre et al., 2000). 
As a further confirmation of their relevance to the same pathway, the 
symptoms resemble each other and overlap in these diseases. Mutations in 
DNM1L are also of clinical importance as they cause early infant mortality 
and cardiomyopathy (Ashrafian et al., 2010; Waterham et al., 2007). 
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Figure 1 A model of mitochondrial fission. 1) Mitochondrion accumulates damage due to 
either external or internal factors. 2) Fission may start with compartmentalization of 
accumulated damage. The inner membrane forms two different compartments. Dynamin 1 
like –protein (DNM1L) attaches to a receptor and marks the site of division. 3) The 
mitochondrion splits into two organelles: one healthy and one harbouring the damaged 
particles. This remnant can be processed further, either by mitophagy, which involves 
autophagosome (gray organelle) or by fission into the larger mitochondrial network (not 
shown). 
Mitophagy, a quality control pathway of mitochondria, works closely with 
the  help  of  mitochondrial  dynamics  [Reviewed  in  (Youle  and  Narendra,  
2011)]. Mitophagy, or mitochondrial autophagy, is the process of catabolism 
of mitochondria. In mammals and yeast, mitophagy is preceded by 
mitochondrial fission to divide the mitochondria into manageable pieces for 
encapsulation (Twig et al., 2008). Mitophagy is also required to maintain 
steady state levels of mitochondria and adjusting the amount of 
mitochondria in the event of stress (Tal et al., 2007). Two important proteins 
in the process are PTEN-induced putative kinase protein 1 (PINK1) and 
parkin, an E3 ubiquitin ligase. The exact mechanism how PINK1 
distinguishes healthy mitochondria from damaged is unknown. However, in 
cell  culture  experiments  PINK1  acts  as  a  recruiting  factor  (Figure  2).  In  
normal conditions, PINK1 is constantly imported into mitochondria, via an 
unknown pathway. When the mitochondrial membrane potential is lost, 
PINK1 import is disrupted and PINK1 immediately accumulates on the 
mitochondrial  outer  membrane,  to  where  parkin  is  recruited  and  bound  
(Narendra et al., 2010). Parkin ubiquitylates specific proteins on the outer 
membrane  using  a  mechanism  that  resembles  endoplasmic  reticulum  
associated degradation (Heo et al., 2010; Xu et al., 2010). The proteins 
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participating in this event include MFN1, MFN2 and Miro, thus linking 
autophagy, MAM and dynamics (Chan et al., 2011; Wang et al., 2011). 
 
Figure 2 A model of PINK1/Parkin induced mitophagy. 1) In normal situation, PINK1 is 
continuously imported to inner membrane, where PINK1 is degraded quickly (light pink 
square = PINK1). 2) When mitochondrial membrane potential is lost, PINK1 import is 
disrupted and it starts to accumulate on the outer membrane, recruiting Parkin. PINK1/Parkin 
complex binds to ubiquitin. 3) PINK1/Parkin/Ubiquitin complex induces the autophagic 
elimination of mitochondria. Grey organelle: Autophagosome 
 Fusion and fission also participate in apoptosis: fusion protects the cell 
from apoptosis  whereas  fission  has  a  positive  role  in  it  (Frank  et  al.,  2001;  
Olichon et al., 2003). These functions strengthen the position that dynamics 
is  a  way  to  control  the  wellbeing  of  individual  mitochondria  and  the  whole  
network.  
4.4 THE STRUCTURE OF A MITOCHONDRION 
The human mitochondrion is a two-membrane-bound organelle, 
characterized by cristae formed by the inner membrane (IM) (Figure 3). The 
outer and inner membranes divide the organelle into the intermembrane 
space  and  the  matrix.  These  areas  provide  the  mitochondria  with  different  
compartments and environment to facilitate its functions. The inner and 
outer  membranes  are  phospholipid  bilayers  with  protein  complexes  
embedded into them. The differences in the contents of the intermembrane 
space and matrix form the basis of the most important mitochondrial 
function, adenosine triphosphate (ATP) generation by the electron transport 
chain (ETC, also known as respiratory chain): an electrochemical gradient 
which is composed from the transport of H+ ions from matrix to the 
intermembrane space through the electron transport chain, is used to 
transform nutrient energy in the conversion of ADP +Pi (Adenosine 
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diphosphate and Inorganic Phosphate) to ATP  when the H+ ions flow back to 
the matrix through ATP synthase (Complex V).  
 
Figure 3 The structure of the human mitochondrion.  
4.4.1 OUTER MEMBRANE 
 
The mitochondrial outer membrane hosts a variety of integral membrane 
proteins, protein complexes and structures, which are involved in the 
transport of proteins from the cytosol to mitochondria (Figure 3) (Schein et 
al., 1976; Wurm et al., 2011). Molecules under 5 kDa are able to freely diffuse 
through membrane pores, whereas larger proteins need a transporter, such 
as translocase of the mitochondrial outer membrane (TOM) [For a review 
(Schleiff and Becker, 2011)]. It also acts as a signalling platform for apoptosis 
and innate antiviral immunity [(Seth et al., 2005) and reviewed in (Bogner et 
al., 2011)].  
4.4.2 INTERMEMBRANE SPACE 
 
The composition of the intermembrane space resembles the cytosol when 
smaller molecules (<5kDa) are considered (Figure 3). Larger molecules have 
to be transported and thus the composition of the intermembrane space  
does not resemble either cytosol or matrix. The intermembrane space also 
harbours cytochrome c, the transporter of electrons between complex III and 
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IV (CIII and CIV). In the case of apoptosis, cytochrome c is released from the 
intermembrane space to cytosol through BCL-2 controlled membrane 
permeabilisation [Reviewed in (Bogner et al., 2011)].  
4.4.3  INNER MEMBRANE 
 
The folds of the inner membrane form cristae, which increase the surface 
area of the membrane but also form different functional regions across the 
inner membrane (Figure 3). In S. cerevisiae the  cristae  are  formed by  F1F0 
ATP synthase dimers, which deform the lipid bilayer of the inner membrane 
by forming a row of ATP synthases, which curve the bilayer into cristae 
(Davies  et  al.,  2012).  The  inner  boundary  region  is  closely  apposed  to  the  
outer membrane and thus functions in protein and lipid trafficking and 
respiratory chain complex assembly.  Cristae project inside the matrix, house 
assembled respiratory complexes and act as a site for mitochondrial DNA 
(mtDNA)  replication  (Figures  3  and  6)  (Brown  et  al.,  2011;  Vogel  et  al.,  
2006). Crista junctions, between the boundary region and cristae, connect 
these two structures together with tubular structure (Perkins et al., 1997).   
4.4.4 MATRIX 
 
The mitochondrial matrix contains necessary enzymes for the complete citric 
acid cycle. It also contains mtDNA, ribosomes and acts as the main Ca2+ 
storage site (Figure 3) (Rossi and Lehninger, 1964).  
 
The  storage  of  Ca2+ is not a passive process in mitochondria. Instead, 
mitochondria are able to rapidly import and export Ca2+. The import of Ca2+ 
is mediated via mitochondrial Ca2+ uniporter (MCU) (Figure 3). The activity 
and biochemical properties of MCU have been characterized long ago, but 
the protein itself has remained elusive until recently [(Baughman et al., 2011; 
De  Stefani  et  al.,  2011)  and  for  a  review (Carafoli,  2003)].  The  Ca2+ uptake 
system is exposed to microdomains of high [Ca2+], in the vicinity of 
endoplasmic reticulum and plasma membrane Ca2+ channels, which explains 
the rapid reaction to cell stimuli (Rizzuto et al., 1993; Rizzuto et al., 1998). 
Matrix [Ca2+] increases stimulate aerobic metabolism in mitochondria, as 
well as sensitizing mitochondria to apoptotic stimuli (Hajnoczky et al., 1995; 
Jouaville et al., 1999; Pinton et al., 2001). Ca2+ is exported from mitochondria 
to the cytosol  via Na2+/ Ca2+ and possibly H+/Ca2+ exchangers (Jiang et al., 
2009; Palty et al., 2010). In neurons,  Ca2+ ions are required for neuronal 
survival, but too high concentrations lead to cell injury and death (Penn and 
Loewenstein, 1966; Simon et al., 1984). 
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4.5 NUCLEUS AND MITOCHONDRIA 
Unlike  other  cellular  organelles,  mitochondria  and  nucleus  have  their  own  
genomes,  mtDNA  and  nuclear  DNA  (nDNA)  (Nass  and  Nass,  1963).  
Mitochondria are not able to function independently, however, as the human 
mitochondrial genome encodes only  37 genes: 13 are subunits for respiratory 
complexes, 22 for mitochondrial transfer ribonucleic acids (RNA) and 2 for 
ribosomal RNAs (Anderson et al., 1981). The respiratory subunits form the 
most  conserved  part  of  the  respiratory  chain  complexes  (Yip  et  al.,  2011).  
This is a tiny portion of the total ~1500 proteins that are currently thought to 
be imported and to take part directly in the function of mitochondria 
(Mootha et al., 2003; Pagliarini et al., 2008; Sickmann et al., 2003).  
 
The relationship of mitochondria and nucleus is not biased, as 
mitochondria produce signals of the metabolic state, affecting the nuclear 
responses. Adenosine monophosphate (AMP)/adenosine triphosphate (ATP) 
and nicotinamide adenine dinucleotide (NAD+/NADH) ratios, and Acetyl 
Coenzyme A (Acetyl-CoA) levels are sensed by AMP-activated protein kinase, 
sirtuin 1 and histone acetyltransferase KAT2A (GCN5), which act through 
peroxisome proliferator-activated receptor gamma coactivator 1-alpha, a 
transcription coactivator and ultimately affect the transcription of genes 
involved in energy metabolism (Canto et al., 2009; Canto et al., 2010; Jager 
et al., 2007; Lerin et al., 2006).  
4.6 MITOCHONDRIAL DNA 
The size and organization of mtDNA varies by species. In humans, mtDNA is 
circular,  double-stranded  DNA  with  a  length  of  16569  base  pairs  (bp).  
However, some plants such as muskmelon may have mitochondrial DNA as 
long  as  2.8  Mb  (Rodriguez-Moreno  et  al.,  2011).  The  mtDNA  is  not  always  
circular as some species also have linear organization (Grant and Chiang, 
1980).  Unlike  nDNA,  the  copy  number  of  mtDNA  in  human  cells  varies  
usually between 100-10000 copies. Usually, the mtDNA population is 
homoplasmic: just one mtDNA genotype exists in the organism (Figure 4-1). 
In heteroplasmy, two or more different mtDNA populations exist in the same 
cell (Figure 4-2). Heteroplasmy is important in the context of disease, as one 
of  the  mtDNA  genotypes  may  harbour  a  disease  causing  mutation  (Holt  et  
al., 1990; Wallace et al., 1988). Homoplasmic mtDNA mutations are 
considered to be incompatible with life in general, but several descriptions of 
diseases caused by homoplasmic mtDNA mutations exist (Degoul et al., 
1995; Gotz et al., 2012; Tulinius et al., 1995). Most likely, homoplasmic 
mutations are more common than previously thought. 
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Figure 4 Mitochondrial genetics. mtDNA mitochondrial DNA. For simplicity, in this picture 
yellow mitochondria represent mitochondria with just one mtDNA population (1, 
Homoplasmy) and red mitochondria represent mitochondria with several mtDNA populations, 
of which at least one is mutated (2, Heteroplasmy). 1) During oocyte maturation, the copy 
number of mtDNA per cell gets lower and daughter cells have lower copy number of mtDNA. 
This is called the bottleneck effect. 2) During oocyte maturation, the mtDNA copies are 
randomly distributed. 3) and 4) During the development of the oocyte, mtDNA copies are 
randomly replicated. However, mitochondria are able to withstand a certain amount of 
heteroplasmy (3). When the threshold for disease is passed (4), clinical symptoms start to 
develop. The threshold is specific for each tissue and mtDNA mutation. 
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Mitochondrial DNA is exclusively maternally inherited. In fact, paternal 
mitochondria are actively degraded during fertilization (Al Rawi et al., 2011; 
Sato  and  Sato,  2011).  When  a  fertilized  oocyte  starts  dividing,  the  mtDNA  
copy  number  per  cell  drops  dramatically.  This  has  several  consequences:  if  
mtDNA population is heteroplasmic, the random replication of mtDNA 
molecules can lead to increased ratio of mutated mtDNA molecules (Figure 
4-3  and  4-4)  (Wai  et  al.,  2008).  This  is  called  the  genetic  bottleneck.  The  
second consequence is that when the amount of mutated mtDNA reaches a 
certain level, called threshold, disease and its symptoms develop (Figure 4-4) 
(Miyabayashi et al., 1992; Shoffner et al., 1990; Wallace, 1986). This also 
means that mitochondria are able to withstand a certain amount of mtDNA 
damage or mutated mtDNA molecules. Organisms have also a strong 
evolutionary pressure for mtDNA homoplasmy and against deleterious 
mtDNA mutations, especially in the protein coding regions(Fan et al., 2008; 
Stewart et al., 2008). 
 
4.7 ORGANIZATION OF MITOCHONDRIAL NUCLEOIDS 
Mitochondrial DNA is organized in nucleoids, which are divided evenly 
throughout the mitochondrial matrix (Satoh and Kuroiwa, 1991). One 
nucleoid has 1-10 mtDNA molecules attached, in addition to proteins and 
RNA (Brown et al., 2011; Kukat et al., 2011). In mammals, the most abundant 
nucleoid protein is mitochondrial transcription factor A (TFAM) (Kaufman et 
al., 2007; Larsson et al., 1998). One mtDNA molecule has approximately 450 
binding sites for TFAM and it binds mtDNA efficiently with two high-
mobility group boxes (Fisher et al., 1992; Kaufman et al., 2007). In addition, 
it also functions as a transcription factor and is able to bind mtDNA strongly 
at promoters. TFAM is a strong regulator of mtDNA copy number, a dramatic 
decrease in mtDNA copy number is  observed in TFAM knock-out mice and 
results in embryonic lethality whereas overexpression of TFAM leads to 
increased  mtDNA  copy  number  (Ekstrand  et  al.,  2004).   LON  protease  
regulates  the  TFAM  protein  level  in  Drosophila Melanogaster (D. 
Melanogaster)  cells  and  thus  mtDNA  copy  number  (Matsushima  et  al.,  
2010). 
 
The structure of mitochondrial nucleoids has been recently studied using 
superresolution microscopy (Brown et al., 2011; Kukat et al., 2011). With 
superresolution microscopy, resolutions approaching 20-50 nm in the lateral 
dimension are achievable, thus making these techniques able to recognize 
structures inside the matrix, between cristae (average span between cristae is 
~68 nm). The studies were performed using several different cell lines: 
human primary fibroblasts, several human cancer cell lines, mouse 
fibroblasts and kidney cells from two different organisms. There were 1-6 
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copies of mtDNA per nucleoid, according to both studies. Both published 
studies arrived at different conclusions about the size and shape of the 
mitochondrial nucleoids: Kukat and co-workers report uniform diameter and 
size, ~100 nm, per nucleoid whereas Brown and co-workers state a large 
variation in the size as within one standard deviation there was 25-fold 
variation  in  the  volume.  In  addition,  Brown and  co-workers  report  that  the  
nucleoids had multiple shapes, ellipsoidal nucleoids being the most common 
(35%). Brown and co-workers conclude that the large variation in ellipsoidal 
nucleoid  volume  is  strongly  influenced  by  the  genome  content  of  nucleoid.  
Other shapes suggested interaction and binding with the inner membrane. 
For an ellipsoidal shape, they calculated that on average the TFAM/mtDNA 
ratio is enough for TFAM to cover all mtDNA molecules in a cell. For other 
shapes, this is not the case and it suggests that other nucleoid proteins, 
currently unknown, stabilize mtDNA in other nucleoid conformations. A 
plethora of different proteins are associated with the nucleoid complex, such 
as ribosomal proteins, chaperones, quality control proteins, helicase and 
RNA binding proteins.   
 
In human cells, nucleoids seem to function in connection with the actin 
network, thus connecting the mitochondrial DNA and nucleoids to a cellular 
support structure and suggesting they may take part in the movement of 
mitochondria (Iborra et al., 2004; Reyes et al., 2011). In yeast, the replisome 
locates  to  a  membrane  spanning  protein  complex  (Boldogh  et  al.,  2003;  
Meeusen  and  Nunnari,  2003).  This  complex  spans  both  inner  and  outer  
membranes and links to the actin network outside mitochondria. The 
minimal two-membrane structure is composed of Mip1 (DNA polymerase, 
homolog of POLG1), Mmm1 (Outer membrane protein) and Mgm101 (DNA 
binding protein). The two-membrane structure may function as a replication 
factory, mtDNA position stabilizer or something else. Although the two-
membrane structure has been found in S. cerevisiae,  no  mammalian  or  
human equivalent has been found so far. Other strong differences between 
mammalian and yeast mtDNA replication exist, such as lack of the DNA 
polymerase gamma accessory subunit and as such, the two-membrane 
structure might be a yeast specific feature (Lucas et al., 2004). 
4.8 MITOCHONDRIAL REPLISOME 
The minimal mitochondrial replisome is composed of POLG, TWINKLE and 
mtSSB in vitro,  as  they  are  able  to  replicate  mtDNA  sized  and  pre-primed  
circular templates (Korhonen et al., 2004). However, based on the current 
models of mtDNA replication, these few proteins are clearly not enough to 
replicate mtDNA in vivo: mitochondrial RNA polymerase (POLRMT) is 
required to transcribe mtDNA and thus produce an RNA primer for the 
initiation of leading strand synthesis and possibly also for the lagging strand. 
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TFAM and mitochondrial  transcription  factor  2B  (TFB2M) are  required  for  
the initiation of transcription. Although transcription and replication of 
mtDNA are strongly linked, it is not known how these processes work 
together. Further, an in vitro model for transcription and replication of 
mtDNA working in tandem has not been produced yet (Fuste et al., 2010). 
4.8.1 DNA POLYMERASE GAMMA 
 
The mitochondrial DNA polymerase, DNA polymerase gamma, is the only 
known DNA polymerase that functions in mitochondria. In humans, DNA 
polymerase gamma is a holoenzyme, consisting of one catalytic core (POLG1) 
and two accessory subunits (POLG2) (Gray and Wong, 1992; Yakubovskaya 
et al., 2005). The catalytic core is a 140 kDa protein encoded by POLG1 
(Bolden et al., 1977; Lecrenier et al., 1997). The catalytic core consists of 3’-5’ 
exonuclease and polymerase domains, which are separated by a spacer 
region. Both exonuclease and polymerase domains have in total six highly 
conserved sequence motifs: Exo I, II and III for the exonuclease domain and 
Pol A, B and C for the polymerase domain (Figure 5). In the spacer region, 
four conserved sequence blocks can be identified: ?1, ?2, ?3 and ?4 (Figure 5) 
(Luo and Kaguni, 2005). 
 
Figure 5 Linear structure of human POLG1. Exo I, II and III: conserved sequence motifs of 
exonuclease domain. ?1, ?2, ?3 and ?4: conserved sequence blocks of exonuclease domain. 
Pol A, B and C: Conserved sequence motifs of polymerase domain. 
 The accessory subunit is a 55 kDa protein, encoded by POLG2. It also has 
three conserved domains (Fan et al., 2006). Although it mainly functions in 
increasing processivity of the holoenzyme, accessory subunit is able to bind 
double  stranded  DNA (dsDNA)  alone  (Carrodeguas  et  al.,  2002;  Fan  et  al.,  
2006;  Lim  et  al.,  1999).  POLG2  is  required  for  the  function  of  the  mtDNA  
replisome and it takes part in determining the mtDNA content of 
mitochondrial nucleoids (Di Re et al., 2009; Farge et al., 2007). 
 
The catalytic core is able to polymerize and bind DNA alone, without the 
help of the accessory subunits (Gray and Wong, 1992; Wernette and Kaguni, 
1986). However, the overall processivity of the enzyme is raised as much as 
100-fold with the help of accessory subunits (Fan et al., 2006; Johnson et al., 
2000;  Lim et  al.,  1999).  In  addition,  the  fidelity  of  the  enzyme is  increased  
with the accessory subunit. The catalytic subunit also has 5?-deoxyribose 
phosphate (dRP) lyase activity, which works in DNA repair by removing the 
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dRP moiety, thus making the single nucleotide gap filling possible (Longley 
et al., 1998b). 
 
DNA polymerase gamma is adaptable in the conditions required for DNA 
polymerase activity: broad pH range (7.5-9.5), ability to use various primer-
templates and moderate to high salt concentration. POLG does require a 
divalent cation and has high affinity for deoxyribonucleotides (dNTP) and is 
able to achieve the highest polymerase activity with high primer-density 
natural  sequence  DNA,  such  as  gapped  double  stranded  calf  thymus  DNA,  
which is routinely used in the DNA polymerase assays (Wernette and Kaguni, 
1986). POLG is also able to utilize natural sequence RNA as a template, 
although not as effectively as natural sequence DNA (Murakami et al., 2003). 
On singly-primed, natural sequence M13 DNA, the human catalytic core has 
processivity of 50 nt, but the reconstituted holoenzyme is able to produce 
products  up  to  7  kb  (Johnson et  al.,  2000;  Lim et  al.,  1999;  Longley  et  al.,  
1998a).  The  catalytic  core  is  able  to  replicate  short  stretches  of  DNA alone,  
without the accessory subunit. This may have relevance in mtDNA repair, in 
which POLG1 is known to participate and might act without the accessory 
subunit (Mitra et al., 2007; Pinz and Bogenhagen, 2005). 
 
POLG is a member of the family A DNA polymerase group. The basic 
structure of the POLG catalytic core (right-hand configuration with thumb, 
palm and fingers) is very close to other members of the Pol I family, but the 
spacer makes it unique (Lee et al., 2009). The spacer domain can be divided 
into intrinsic processivity (IP) and accessory interacting determinant (AID) 
subdomains (Lee et al., 2009). The IP subdomain has active residues, which 
bind upstream of the primer-template DNA (ptDNA) and explain the high 
intrinsic polymerase activity of the catalytic core alone, compared to other 
Pol I family polymerases. Whereas the IP subdomain takes part directly in 
the polymerase activity, the AID subdomain forms an important interface 
with POLG2.  
 
The POLG holoenzyme is a heterotrimer in mammals (Gray and Wong, 
1992;  Olson  et  al.,  1995;  Yakubovskaya  et  al.,  2005).  The  two  accessory  
subunits interact differently with the catalytic core, with one being the 
proximal and the other the distal subunit (Lee et al., 2009; Lee et al., 2010b). 
The proximal subunit has a plethora of interactions with the catalytic core, 
both hydrophilic and hydrophobic. Deletion and mutation of the 
hydrophobic residues result in almost complete lack of subunit interaction 
and diminish the polymerase activity of the holoenzyme to the same level as 
catalytic  core  alone  (Fan  et  al.,  2006).  The  distal  subunit  has  only  a  direct  
interaction with the catalytic core through only one salt bridge and one van 
der Waals interaction. In Drosophila melanogaster, the POLG holoenzyme is 
indeed able to function with a monomeric accessory subunit (Wernette and 
Kaguni, 1986). The role of the distal accessory subunit is to increase the 
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polymerization rate of the POLG holoenzyme, whereas the proximal 
accessory subunit increases the DNA binding affinity of the holoenzyme (Lee 
et al., 2010a; Lee et al., 2010b). This increase does not come without a cost, 
as POLG2 stimulation of the POLG1 DNA synthesis is partly through 
diminishing  the  exonuclease  activity  of  the  holoenzyme (Farge  et  al.,  2007;  
Johnson and Johnson, 2001a). The accessory subunit and the spacer region 
are features of metazoans. For example, S. cerevisiae does not have either 
(Foury, 1989; Ropp and Copeland, 1996).  
 
Human  POLG  holoenzyme  has  high  fidelity,  with  just  one  error  per  3  x  
105 base pairs, compared for example to the rat Pol ?, which has an error rate 
of  one  error  per  1600-51000  base  pairs  (Ahn  et  al.,  1997;  Johnson  and  
Johnson,  2001b;  Kaguni  and  Olson,  1989).  This  high  fidelity  is  due  to  
exonucleatic proofreading activity of the holoenzyme and high nucleotide 
selectivity  (Johnson  and  Johnson,  2001a;  Johnson  and  Johnson,  2001b;  
Longley et al., 2001). The error rate is modified by several factors: nucleotide 
pool imbalances, abasic sites and oxidative damage on the template DNA 
(Kunkel and Soni, 1988; Pinz and Bogenhagen, 1998; Wernette and Kaguni, 
1986). This is clinically relevant, as for example, mutations in ANT1 (adenine 
nucleotide translocator 1) and RRM2B (ribonucleotide reductase M2 B) 
mutations cause progressive external ophthalmoplegia (PEO), a syndrome 
characterized with multiple mtDNA deletions, and  TYMP (a gene involved in 
the nucleotide salvage pathway) mutations lead to mtDNA depletion 
(Kaukonen et al., 2000; Nishino et al., 1999; Tyynismaa et al., 2009).  
 
The high fidelity of the POLG holoenzyme is partly achieved due to the 3’-
5’ exonuclease activity of the holoenzyme. The exonuclease activity of POLG 
requires the same broad conditions as polymerase activity and seems to have 
a clear preference for dsDNA containing 3’-terminal mispairs (Kaguni and 
Olson,  1989;  Kunkel  and  Mosbaugh,  1989;  Kunkel  and  Soni,  1988).  POLG  
exonuclease mispair specificity is high and the cost of proofreading during 
DNA synthesis low (Kaguni and Olson, 1989; Longley and Mosbaugh, 1991). 
The ability to transfer a mispaired 3’-terminus of the DNA strand from pol to 
the exonuclease domain and the 10-fold higher dissociation from the pol 
active site, in the case of mispaired rather than correctly paired 3’-terminus, 
result  in  20  to  200  fold  increase  in  fidelity  of  the  enzyme  (Johnson  and  
Johnson, 2001a).  
4.8.2 HELICASE TWINKLE 
 
Human  mitochondrial  DNA  helicase,  TWINKLE,  which  is  encoded  by  
C10ORF2 was discovered in 2001 (In this thesis, Twinkle  is used as synonym 
for C10ORF2) (Spelbrink et al., 2001). Similar to other components of 
mitochondrial DNA replication machinery, it resembles the T7 gene product 
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4 primase-helicase (T7 GP4). The highest homology between human 
TWINKLE and T7 GP4 is in the helicase domain, which supports the fact that 
the human TWINKLE does not have any primase activity (Farge et al., 2008; 
Spelbrink et al., 2001). In addition, bioinformatic analysis  of mammalian 
TWINKLE sequences show that it has lost the required primase domains for 
actual synthesizing the short RNA primers (Shutt and Gray, 2006). The size 
of TWINKLE protein is 684 amino acids. A splice variant named TWINKY, 
which  lacks  the  amino  acids  579-684,  was  found  together  with  TWINKLE,  
but the function and relevance of TWINKY is still unknown (Spelbrink et al., 
2001). TWINKLE, as other replicative helicases, forms a hexameric ring 
(Farge et al., 2008; Ziebarth et al., 2007; Ziebarth et al., 2010). However, it 
does  also  form a  heptameric  ring  routinely.  This  structure  is  not  limited  to  
TWINKLE, as some other helicases, such as Methanobacterium 
thermoautotrophicum minichromosomal maintenance protein also form this 
structure, however the function or relevance is again unknown (Yu et al., 
2002; Ziebarth et al., 2010). TWINKY, however, is unable to form oligomeric 
structures with itself or TWINKLE. Recombinant TWINKLE has strong 
ATPase  activity  and  it  unwinds  DNA  in  5’  to  3’  direction  (Korhonen  et  al.,  
2003).  
 
Human recombinant TWINKLE is able to bind circular single stranded DNA 
(ssDNA) (Jemt et al., 2011). After the hexameric ring has bound circular 
ssDNA, TWINKLE is able to stay bound longer than on linear ssDNA. 
TWINKLE is also able to start unwinding ssDNA with an oligomer primer on 
its own. Together with POLG, they are able to replicate through an artificial 
dsDNA bubble (resembling human mtDNA D-loop structure) (Jemt et al., 
2011). Mitochondrial single-stranded DNA binding protein (mtSSB) is able to 
stimulate the helicase activity of TWINKLE, but it does not inhibit the 
unwinding of dsDNA, when the template is coated with mtSSB (Jemt et al., 
2011). Taken together, these results show that TWINKLE is able to function 
on a mtDNA-like template, together with other proteins of the replisome. 
4.8.3 MITOCHONDRIAL SINGLE-STRANDED DNA BINDING PROTEIN 
 
Unlike mitochondrial helicase and DNA polymerase, the mtSSB does not 
share  homology  with  its  T7  counterpart.  MtSSB shares  50% similarity  with   
Escherichia coli single stranded binding protein (E.coli SSB) deduced amino 
acid sequence and its tertiary structure and functionality resembles E. coli 
SSB closely (Tiranti et al., 1993; Webster et al., 1997; Yang et al., 1997). 
Human mtSSB is a homotetramer; it binds ssDNA to protect ssDNA against 
damage and to coordinate the function of other proteins of the replisome 
(Korhonen et al., 2004; Yang et al., 1997). MtSSB has been shown to increase 
the  activities  of  the  other  proteins  in  the  replisome:  POLG  and  TWINKLE,  
and the overall function of the replisome (Korhonen et al., 2004). Knock-
  25
down  or  knock-out  of  mtSSB  in  both  human  cells  and  D. melanogaster 
results in reduced mtDNA copy number (Farr et al., 2004; Farr et al., 1999; 
Maier et al., 2001; Oliveira and Kaguni, 2010; Ruhanen et al., 2010).  
4.8.4 MITOCHONDRIAL RNA POLYMERASE 
 
POLRMT and transcription factors (TFAM, TFB2M) form the basal 
mitochondrial transcription machinery (Falkenberg et al., 2002; Litonin et 
al., 2010). In addition to transcription, POLRMT acts as the mitochondrial 
primase (Chang and Clayton, 1985; Chang et al., 1985; Fuste et al., 2010; 
Wanrooij et al., 2008). POLRMT has been proposed to generate the RNA 
primers  required  for  the  initiation  of  both  leading  and  lagging  strand  
synthesis. The synthesis of the leading strand (heavy strand) is primed by an 
RNA primer generated by POLRMT from the transcription initiation from 
light strand promoter (LSP) (Chang and Clayton, 1985). This primer is 
extended by POLG, but the majority of initiation events are terminated inside 
the D-loop, about 600 bp from the LSP promoter. These terminated strands 
stay hybridized to the parental mtDNA molecule, thus forming a triplex 
structure, the D-loop (Arnberg et al., 1971; ter Schegget et al., 1971).  
 
The initiation of lagging strand DNA synthesis requires that the leading 
strand synthesis has advanced about 2/3 of the mtDNA, exposing a non-
coding DNA, which contains the origin of lagging strand (Kang et al., 1997; 
Martens and Clayton, 1979). This exposed non-coding region takes the shape 
of  a  stem-loop,  from  which  POLRMT  is  proposed  to  synthesize  the  RNA  
primer in a sequence and secondary structure dependant manner (Fuste et 
al., 2010; Wanrooij et al., 2008). As the mtDNA replication model is a highly 
debatable subject, it can be summarized that the full role of POLRMT in 
mtDNA initiation is still under debate. 
4.9 REPLICATION OF MTDNA 
The replication of mtDNA was first described to be strand-asynchronous, 
with strand-specific origins of replication (Figure 6-1)(Berk and Clayton, 
1974). This model was challenged by results achieved by using two-
dimensional agarose gel electrophoresis. Two-dimensional agarose gel 
electrophoresis  is  an established method,  which is  used to study replication 
intermediates and the replication fork. The two-dimensional agarose gel 
electrophoresis results supported an alternative explanation for mtDNA 
replication as having the following features: bidirectional, strand-coupled 
replication,  resembling  dsDNA  replication  seen  in  the  nucleus  (Figure  6-2)  
(Bowmaker et al., 2003; Holt et al., 2000; Yang et al., 2002). Instead of two 
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origins of replication, there would be an initiation zone, approximately 4 kb 
in size, from which the replication of both strands would begin.  
 
The controversial bidirectional, strand-coupled mtDNA replication model 
was refuted with atomic force microscopy. Brown and co-workers did not 
find  any  reasonable  proof  to  support  strand-coupled  DNA replication,  such  
as  Cairns  structures  or  dsDNA  replication  forks  (Brown  et  al.,  2005).  They  
did  find,  however,  gapped  circle  structures,  which  are  incompatible  with  
strand-coupled DNA synthesis, but required for strand-asynchronous DNA 
replication. They found also evidence for possible alternative light-strand 
origins,  but  the  relevance  of  these  remains  to  be  elucidated.   Later,  the  
strand-coupled mtDNA replication model was refined when it was found that 
the  lagging  strand  is  initially  laid  down  as  RNA,  before  being  converted  to  
DNA (Figure 6-3) (Yang et al., 2002; Yasukawa et al., 2006; Yasukawa et al., 
2005). This new model was named ribonucleotide incorporation throughout 
the lagging strand (RITOLS). Further studies have confirmed the existence of 
stable, long RNA intermediates on the lagging strand (Brown et al., 2008). 
The role of these intermediates is unclear: they may be processed to form 
RNA primers for the lagging strand, but some studies have not found proof to 
confirm this (Brown et al., 2008). 
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Figure 6 Models of mitochondrial DNA replication. Yellow: light (lagging) strand. Green: 
heavy (leading) strand. Burgundy: replicating heavy strand. Purple: replicating light strand. 
Light blue: Newly synthesized RNA strand OH: origin of heavy strand. OL: origin of light 
strand. OR: origin of RITOLS leading strand. 1) Strand- asynchronous model of 
mitochondrial DNA replication. The replication begins from the OH from RNA primer made by 
mitochondrial RNA polymerase. When the replication of heavy strand reaches OL , it forms a 
stem-loop, to which mitochondrial RNA polymerase synthesis the RNA primer for the light 
strand and from the replication of the light strand begins. 2) Bidirectional, strand-coupled 
mtDNA replication model. The replication of both strands begins from multiple zones, 
downstream from OH and continues bidirectionally. 3) Ribonucleotide incorporation 
throughout the lagging strand (RITOLS) model of mitochondrial DNA replication. The 
replication of heavy strand begins from discrete origin, OR and continues unidirectionally. At 
the same time, the displaced lagging strand is initially laid down as RNA. When the heavy 
strand replication reaches OL , the new RNA copy of lagging strand is replaced by DNA 
strand. 
Although the controversy is still far from over, we can conclude that since 
2008, no major challenges have been presented to the current RITOLS 
model of mtDNA replication. The RITOLS model resembles the original 
strand-asynchronous model as transcription of the light strand provides the 
RNA primer required for the initiation of mtDNA replication at the heavy 
strand origin (Figure 6-3). The heavy strand, or leading strand, is replicated 
about two thirds and concomitantly covered by RNA, until the replication 
fork  arrives  at  the  light  strand  origin.  The  ssDNA  forms  a  stem-loop,  from  
which POLRMT synthesizes an RNA primer. On the light, or lagging strand, 
DNA maturation begins from this primer: the RNA primers are removed with 
the help of ribonuclease 1, DNA replication helicase 2 homolog and flap 
structure-specific endonuclease 1, and the gap is filled by POLG.  
4.10 REPAIR OF MTDNA 
The  10-50  fold  higher  rate  of  mutation  accumulation  in  mtDNA  than  in  
nDNA and higher levels of oxidative damage to mtDNA puts mtDNA repair 
mechanisms  in  focus;  indeed,  some  time  ago  the  whole  concept  of  mtDNA  
repair was questionable, but now current research has confirmed that most 
of DNA repair pathways exist also in mitochondria. 
4.10.1 SOURCES OF MTDNA DAMAGE 
 
The most important cause of mtDNA damage is intrinsic factors, such as 
reactive species, which are produced during the normal metabolism of the 
mitochondria and due to external factors. Both ROS and nitrogen species 
(RNS) are found inside mitochondria. ROS are produced during oxidative 
phosphorylation as electrons are transported through the ETC, with the final 
destination of an oxygen molecule. However, 0.2% of electrons are 
transported to oxygen prematurely from complexes I and III, leading to 
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formation  of  superoxide  radicals,  which  can  be  converted  to  hydrogen  
peroxide [Reviewed in (Murphy, 2009)]. ROS can damage mtDNA and lead 
to formation of modified bases, sugar break down products, base-free sites 
and strand breaks [Reviewed in (Cooke et al., 2003)].  
 
Peroxynitrite, a RNS, is produced from nitric oxide and superoxide anion. 
Peroxynitrite is able to oxidize DNA bases and fragment sugar, thus leading 
to  strand  breaks  (Burney  et  al.,  1999a;  Burney  et  al.,  1999b).  A  second  
important RNS is nitrous anhydride, which can deaminate primary amines of 
DNA bases and produce abasic sites (Burney et al., 1999b). 
 
During the replication of mtDNA, POLG may also incorporate oxidized 
bases, thus leading to mtDNA damage. Mitochondria have various defense 
mechanisms against ROS and other stressors, such as antioxidants. In 
addition, specific enzymes that degrade oxidized nucleotides in the dNTP 
pool exist (Fujikawa et al., 1999). Furthermore, POLG has a 3’-5’ exonuclease 
function that proofreads the newly synthesized DNA strand.  
4.10.2 MECHANISMS OF MTDNA REPAIR 
4.10.2.1 Base excision repair 
 
The base excision repair (BER) pathway is the best characterized repair 
pathway in mitochondria. Both short- and long-patch BER (Single nucleotide 
and 2-6 nucleotides, respectively) exist in mammalian mitochondria (Akbari 
et  al.,  2008;  Liu  et  al.,  2008;  Stierum  et  al.,  1999b;  Szczesny  et  al.,  2008;  
Zheng  et  al.,  2008).  Short  patch  base  excision  repair  is  important  in  
removing single lesions, whereas long-patch base excision repair is part of 
mtDNA replication in removing the RNA primers (Zheng et al., 2008). 
 
In both short patch and long-patch base excision repair, the lesion such as 
8-hydroxyguanine (the major oxidative lesion in mitochondria) is first 
removed by a DNA glycosylase. The remaining abasic nucleotide or 
nucleotides  are  then  removed  by  AP  endonuclease  and  the  gap  is  filled  by  
POLG (Mitra et al., 2007; Pinz and Bogenhagen, 1998). Then, the remaining 
displaced dRP (short patch base excision repair) or nucleotide flap (long-
patch base excision repair) is cleaved. POLG is able to remove a single dRP 
from  short  patch  base  excision  repair.  In  comparison  to  short  patch  base  
excision repair, in long-patch base excision repair the ssDNA flap is removed 
by DNA2 (nuclease/helicase) and FEN1. DNA2 cleaves ssDNA internally and 
finally FEN1 cleaves ssDNA in the junction of ssDNA and dsDNA (Liu et al., 
2008; Zheng et al., 2008). While removing RNA primers the substrate is first 
cleaved by RNaseH1, and then filled by POLG, and the ssDNA flap is 
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removed  by  DNA2  and  FEN1  (Cerritelli  et  al.,  2003).  Finally,  the  newly  
synthesized DNA patch is joined to the downstream sequence by DNA Ligase 
3 (Lakshmipathy and Campbell, 1999b). 
 
The removal of damaged nucleotides via DNA glycosylase and lyase is 
damage-specific. For example, 8-hydroxyguanine is removed by 8-
Oxoguanine glycosylase, uracil is removed by uracil-DNA glycosylase, and 
thymine glycol is removed by endonuclease III family glycosylases (Dobson 
et al., 2000; Nilsen et al., 1997; Nishioka et al., 1999; Stierum et al., 1999a).  
Removal  of  an  abasic  nucleotide  is  catalyzed  by  APE1  or  APE2,  which  both  
exist in the nucleus and mitochondria (Mitra et al., 2007; Tsuchimoto et al., 
2001). 
4.10.2.2 Mismatch repair 
 
In  mismatch  DNA  damage,  a  wrong  nucleotide  is  inserted  into  the  newly  
synthesized DNA strand. The presence of the mismatch repair pathway in 
mitochondria has been confirmed in two independent studies, first using rat 
liver mitochondrial extracts and then human cells (de Souza-Pinto et al., 
2009;  Mason et  al.,  2003).  It  was  also  established  in  these  studies  that  the  
classical nuclear mismatch repair proteins do not locate to mitochondria. It 
seems that the mismatch binding activity is due to Y-box binding protein YB-
1. However, the exact characteristics of this pathway are still unknown. 
4.10.2.3  Double-strand break repair 
 
As in other mechanisms of mtDNA damage repair, the knowledge of double-
strand break repair is limited. We know from patients that recombination 
intermediates have been identified (Kajander et al., 2001; Kraytsberg et al., 
2004; Poulton et al., 1993). Also, in in vitro studies, it has been shown that 
mammalian mitochondrial extracts have activity for homologous 
recombination and end-joining activities (Coffey et al., 1999; Lakshmipathy 
and Campbell, 1999a). Heteroplasmic mice with inducible expression of 
restriction endonucleases, to create double-strand breaks in mtDNA, did not 
have detectable amounts of mtDNA double stranded breaks. Instead, they 
had mtDNA molecules with deletions, thus confirming existence of double-
strand break repair activity in mammalian mitochondria (Bacman et al., 
2009; Fukui and Moraes, 2009; Srivastava and Moraes, 2005). The 
efficiency of double-strand break repair or possible lack of it is under debate, 
but the evidence for double-strand break repair in mammalian mitochondria 
is strong (Alexeyev et al., 2008; Kukat et al., 2008). 
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4.10.2.4 Nucleotide excision repair 
 
Nucleotide excision repair requires removal of short stretches of damaged 
DNA, which are then refilled.  The existence of  nucleotide excision repair  in 
mitochondria has not been confirmed and classical nucleotide excision repair 
substrates are repaired by alternative mechanisms in yeast (Yasuhira and 
Yasui, 2000). 
4.11 FUNCTIONS OF MITOCHONDRIA 
4.11.1 OXIDATIVE PHOSPHORYLATION 
 
Oxidative  phosphorylation  (OXPHOS)  produces  ATP  from  the  energy  
released  by  the  oxidation  of  nutrients  (Figure  7).  OXPHOS  is  the  most  
conserved function of mitochondria (Yip et al., 2011). Besides being used as 
energy, ADP/ATP also act as signalling molecules in the cell, thus making 
mitochondria signalling centres. The molecular machine required for 
OXPHOS, also known as respiratory chain or electron transport chain, 
residues in the inner membrane of mitochondria and consists of five 
different complexes. 
4.11.1.1 Complex I 
 
Complex  I  (also  referred  to  as  NADH  dehydrogenase)  is  the  largest  of  the  
subcomplexes. CI is constructed from 45 subunits and the total molecular 
mass is ~1000 kDa. The core of CI is highly conserved and is composed of 14 
subunits,  of  which  seven  are  encoded  by  mtDNA  and  seven  are  nuclear  
encoded  (Yip  et  al.,  2011).  All  of  the  other  CI  subunits  are  also  nuclear  
encoded. The energy released by the tricarboxylic acid cycle (TCA, also 
known as  citric  acid  cycle)  is  stored  as  NADH,  which  CI  is  able  to  use  as  a  
substrate (Figure 7). Recent publications of the CI crystal structure from 
Escherichia coli, Thermus thermophilus and Yarrowia lipolytica have 
helped to elucidate the mechanism of action of CI (Berrisford and Sazanov, 
2009; Efremov et al., 2010; Efremov and Sazanov, 2011; Hunte et al., 2010; 
Sazanov and Hinchliffe, 2006). The structure of CI in these organisms can be 
roughly  divided  into  membrane  and  peripheral  arms,  which  form  an  L-
shaped cluster.  The function of CI can be simplified by using the structural 
data: at the top of L, NADH is oxidized and flavin mononucleotide acts as the 
electron acceptor. The released electrons are transported quickly via seven 
iron-sulphur clusters, which form a descriptive electric cord throughout the 
structure, to the quinone binding site, where ubiquinone is reduced to 
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ubiquinol. CI also transports protons from the matrix to intermembrane 
space: the proton transfer is done at the base of CI in the membrane arm via 
antiporters which translocate the protons by a structural change in the 
membrane arm. This change can be oversimplified to resemble the connected 
moving wheels of a locomotive engine. CI is also a prolific producer of ROS 
(Galkin and Brandt, 2005; Kussmaul and Hirst, 2006). 
 
Figure 7 Schematic representation of oxidative phosphorylation. I-IV, complexes I-IV.  Upper 
part: Complex I acts as the main electron entry point to the electron transport chain. NADH, 
produced by citric acid cycle, or tricarboxylic acid cycle, is oxidized by complex I. The 
released electrons are transported through complex III and cytochrome c (Cyt c) to complex 
IV. Complexes I, III and IV all transport protons from matrix to intermembrane space, thus 
building the electrochemical gradient. Finally, the protons are able to flux back to matrix 
through ATP synthase and the energy released is stored by phosphorylation of ADP to ATP. 
Lower part: Complex II may act as the second entrypoint to the electron transport chain. 
Complex II accepts succinate, which is an intermediate product of tricarboxylic acid cycle, 
and oxidizes it to fumarate, reducing ubiquinone in the process. 
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4.11.1.2 Complex II 
 
Complex II (CII) or succinate dehydrogenase (SDH) is the second entry point 
to the ETC (Figure 7). CII is unique among the respiratory complexes in two 
ways: first, it consists of four protein subunits that are all encoded by nuclear 
genes  (Sun  et  al.,  2005).  Second,  CII  is  the  only  subcomplex  of  the  ETC  
which functions in both the TCA cycle and respiratory chain. In the TCA 
cycle, it oxidizes succinate to fumarate and reduces ubiquinone to ubiquinol 
at the same time, thus connecting the TCA cycle and respiratory chain.  
4.11.1.3 Complex III 
 
CIII or ubiquinol:cytochrome c oxidoreductase is a dimer that is constructed 
from 11 proteins, of which one is encoded by mitochondrial DNA 
(cytochrome b) and the rest by nuclear genes (Iwata et al., 1998). It oxidizes 
ubiquinol produced by CI and CII and reduces two molecules of cytochrome 
C. At the same time, it transfers four protons from the matrix to the 
intermembrane space, contributing to the electrochemical gradient (Zhang et 
al., 1998).  
4.11.1.4 Complex IV 
 
CIV or cytochrome C oxidase is  the terminal  oxidizer of  the ETC. It  accepts 
electrons from cytochrome C and uses them to reduce molecular oxygen to 
water. This is done with the help of two copper centers and heme sites in the 
complex (Tsukihara et al., 1995; Tsukihara et al., 1996). In addition, it 
transports four protons across the inner membrane, building up the 
electrochemical gradient even more. CIV is composed of 13 subunits, three of 
which are encoded by mitochondrial DNA and ten by nuclear genes.  
4.11.1.5 ATP synthase 
 
Complex V or ATP synthase forms an ion channel between the 
intermembrane space and the matrix (Abrahams et al., 1994). Through this 
channel protons are able to flow back to the matrix and the energy released 
in this flux is used to phosphorylate ADP with Pi, producing ATP. ATP 
synthase subunits in humans are encoded by two mitochondrial genes and 25 
nuclear genes. In yeast, the F1Fo ATP synthase also functions in the forming 
of cristae folds (Davies et al., 2012).  
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Nutrient energy is not always used to phosphorylate ATP. Instead, it can be 
released  as  thermal  energy  if  mitochondrial  proton  pumping  from  the  ATP  
synthase is uncoupled. In brown adipose tissue, this uncoupling is done by 
thermogenin (Aquila et al., 1985). In total, five putative uncoupling proteins 
have  been  reported  in  mammals,  but  their  function  is  not  well  established.  
Also, artificial uncoupling proteins, such as 2,4-dinitrophenol exists (Tainter 
et al., 1934). They have been used as weight-loss agents, with limited success 
due to their rather narrow therapeutic window. 
4.11.2 ENERGY METABOLISM 
 
Mitochondria release energy from pre-metabolized nutrients by the TCA 
cycle. Acetyl-CoA, which is produced by the metabolism of glucose, amino 
acids and fatty acids, is fed to the TCA cycle. The TCA cycle metabolizes 
Acetyl-CoA into NADH, which is  fed into the OXPHOS system via CI.  Also,  
oxidization  of  succinate,  an  intermediate  product  of  the  TCA  cycle,  to  
fumarate,  is  done  by  CII  and  feeds  electrons  to  the  respiratory  chain.  The  
whole  TCA  cycle  occurs  in  the  matrix.  In  addition  to  the  TCA  cycle,  
mitochondria take part in the urea cycle and beta-oxidation of fatty acids. 
Amino acid catabolism in most cases involves a deamination, in which an 
amino group is moved from the amino acid to alpha-ketoglutarate, which 
forms glutamate. Glutamate is again degraded into alpha-ketoglutarate, 
which enters the TCA cycle, and the amino group, which is processed in urea 
cycle. In the urea cycle, mitochondria convert amino groups from NH4+ into 
citrulline  and  inorganic  phosphate,  which  are  metabolized  further  in  the  
cytosol into urea. In mammals, the urea cycle occurs mostly in liver and to a 
lesser extent in kidneys. As a by-product, two NADH molecules are formed 
and the total amount released is more than what is consumed. Not every 
amino acid is degraded by deamination: in some cases, uric acid or ammonia 
is formed.  In beta-oxidation of fatty acids, fatty acids are first activated in 
the cytosol and then transported into mitochondria via the carnitine-
acylcarnitine translocase, where chains of fatty acids are split into acetyl-CoA 
and can be fed into the TCA cycle. 
4.11.3 OTHER FUNCTIONS OF MITOCHONDRIA 
 
Mitochondria have various functions in addition to energy metabolism: they 
take part in steroid synthesis, iron-sulfur cluster formation and heme 
synthesis. Mitochondria also take part in apoptosis and iron and copper 
metabolism.  
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4.12 MITOCHONDRIAL DNA AND DISEASE 
Mitochondrial diseases are a heterogeneous group of diseases, here restricted 
to include the malfunction of the respiratory chain. The causes are genetic, 
either  in  the  genes  encoded  by  nuclear  0r  mitochondrial  genomes.  
Mitochondrial  myopathy,  the  most  classic  mitochondrial  disease,  is  
characterized by abnormalities in muscle biopsy samples: ragged red fibers, 
cytochrome C oxidase (COX) negative fibers on COX-SDH histochemical 
analysis and abnormal mitochondria on electron microscopy.  
 
Another common feature of mitochondrial disease is abnormalities in 
mtDNA: deletions, point mutations and depletion. Also, duplication of part 
of mtDNA is a particular mutation type occasionally seen in patients, but 
usually together with deletions (Poulton et al., 1989a; Poulton et al., 1989b). 
mtDNA abnormalities can also be divided into acquired and inherited. 
Inherited mtDNA abnormalities, are caused by a direct alteration of mtDNA, 
such as the point mutation m.3243A?G,  the most common cause of 
mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes 
(MELAS) and mitochondrial diabetes mellitus (MDD) (Goto et al., 1990; van 
den Ouweland et al., 1992). Acquired defects, such as multiple deletions and 
mtDNA  depletion,  are  caused  by  malfunction  in  mtDNA  replication,  and  
nucleotide pool imbalances, for example. The mtDNA replication defects are 
due to nuclear gene mutations, such as in POLG1 or C10ORF2 (Spelbrink et 
al., 2001; Suomalainen et al., 1992a; Suomalainen et al., 1997; Van Goethem 
et al., 2001). However, toxic substances such as zidovudine, a nucleoside 
analog reverse-transcriptase inhibitor, can also affect mtDNA replication and 
cause mtDNA depletion (Arnaudo et al., 1991; Lewis et al., 1994). mtDNA 
depletion can be caused by TYMP mutations, which affect the nucleotide 
salvage pathway (Nishino et al., 1999). For example, a common cause of PEO 
is mutations in POLG1, leading to malfunction of POLG and multiple mtDNA 
deletions (Graziewicz et al., 2004; Van Goethem et al., 2001).   
 
Grouping mitochondrial diseases based on the mtDNA rearrangements is 
relevant only in the historical context as the rearrangements were published 
before  it  was  possible  to  study  the  mutations  or  genes  behind  the  diseases  
(Bohlega  et  al.,  1996;  Holt  et  al.,  1988;  Moraes  et  al.,  1989;  Zeviani  et  al.,  
1989). Grouping mtDNA diseases based on mtDNA rearrangements is 
misleading: for instance, mitochondrial neurogastrointestinal 
encephalopathy (MNGIE), may exhibit either multiple mtDNA deletions or 
mtDNA depletion (Hirano et al., 1998). Classification of mtDNA diseases 
based on the mutated gene, is not helpful as mutations in the same gene, or 
even the same mutation, may exhibit great heterogeneity in the clinical 
presentation (Tang et al., 2011; Tzoulis et al., 2006). Due to the 
heterogeneous nature of mitochondrial diseases, no good classification of 
mitochondrial disease exists and most probably will not exist in near future.  
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4.13 DISEASES CAUSED BY POLG1 MUTATIONS 
POLG1 mutations are an important cause of neurodegenerative phenotypes, 
ranging from mitochondrial recessive ataxia syndrome (MIRAS) to 
parkinsonism (Luoma et al., 2004; Luoma et al., 2007; Van Goethem et al., 
2004). Also, POLG1 with proofreading deficiency causes an artificial 
premature  aging  phenotype  in  mice  (Trifunovic  et  al.,  2004).  The  
proofreading deficiency in POLG1 leads to neural and hematopoietic 
progenitor  cell  dysfunction  early  in  embryogenesis,  but  manifests  as  a  
respiratory chain dysfunction in non-dividing tissues in old age (Ahlqvist et 
al., 2012). The clinical spectrum of POLG1 mutations is heterogeneous. Even 
the same mutations in POLG1 can cause different phenotypes, as is evident in 
the  case  of  Alpers’  disease  and  MIRAS.  Also,  the  age  of  onset  and  clinical  
manifestations of disease show great variability. This clinical heterogeneity is 
a pronounced feature of POLG1 diseases and the heterogeneity is not as 
evident in other syndromes caused by malfunction of the mtDNA replication 
machine. For example, IOSCA, which is caused by a mutation in Twinkle, has 
a nearly similar clinical manifestation in every patient (Koskinen et al., 
1994b). However, this heterogeneity of POLG1 diseases might be a biased 
finding due to the higher frequency of POLG1 mutations. Twinkle mutations 
have been reported in Alpers’ disease and PEO with parkinsonism (Baloh et 
al., 2007; Sarzi et al., 2007; Vandenberghe et al., 2009). 
4.13.1 MITOCHONDRIAL RECESSIVE ATAXIA SYNDROME 
 
Mitochondrial recessive ataxia syndrome (MIRAS) was first identified in 
2001 in a Finnish family and its genetic cause was found to be in POLG1 
(Rantamäki et al., 2001; Van Goethem et al., 2004). The common occurrence 
and ancient pan-European origin of the mutation was discovered by 
Hakonen  in  2005  and  the  syndrome  was  named  MIRAS  (or  MSCA-E,  by  
Winterthun). Later, it has been described in patients from Norway, Belgium, 
Australia, New Zealand and United Kingdom (Hakonen et al., 2007a; 
Hakonen et al., 2005; Van Goethem et al., 2004; Winterthun et al., 2005). 
MIRAS is caused by POLG1 mutations, most commonly the homozygous 
mutations c. 2243G?C in cis with c.3428A?G, leading to p.Trp748Ser + 
p.Glu1143Gly amino acid changes, the compound heterozygous mutations c. 
2243G?C in cis with  c.3428A?G  and,  on  the  other  allele,  c.  1399G?A, 
which respectively leads to p.Trp748Ser + p.Glu1143Gly and p.Ala467Thr 
amino acid changes (Figure 5). The carrier frequency of these disease alleles 
is high in Finland and Norway: 0.8% for c. 2243G?C in cis with c.3428A?G 
allele in Finland and 0.5% for combined c. 2243G?C in cis with c.3428A?G 
and c. 1399G?A alleles in Norway (Hakonen et al., 2005; Winterthun et al., 
2005). In Italian, British and Spanish ataxia patient cohorts the high 
frequency of c. 2243G?C in cis with c.3428A?G and c. 1399G?A  alleles 
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has not been replicated, but patients have been described in all Caucasian 
populations (Cagnoli et al., 2008; Craig et al., 2007; Hakonen et al., 2007a; 
Hakonen et al., 2005; Pelayo-Negro et al., 2012). All European patients share 
a common core haplotype in POLG1, indicating a common founder (Hakonen 
et al., 2007a; Hakonen et al., 2005).  
 
The clinical features of MIRAS resemble other mitochondrial ataxias 
closely and differential diagnoses are not possible based solely on clinical 
signs (Table 1) (Hakonen et al., 2005; Rantamäki et al., 2001; Van Goethem 
et  al.,  2004;  Winterthun  et  al.,  2005).  The  typical  age  of  onset  for  MIRAS  
varies  from  five  years  to  50  years.  The  course  of  MIRAS  is  variable:  in  
Norway the median survival is 26 years after diagnosis for patients 
homozygous for  c. 2243G?C in  cis  with  c.3428A?G mutations in POLG1 
(Tzoulis et al., 2006). Patients, who are compound heterozygous for c. 
2243G?C in cis with c.3428A?G mutations and c. 1399G?A have a worse 
prognosis as their median lifespan after diagnosis in Norway is just six years 
(Tzoulis  et  al.,  2006).  However,  in  Finland  the  life  expectancy  is  not  as  
limited (Suomalainen A, unpublished observation). Patients with age of onset 
under 20 years usually present with epileptic seizures or migraine-like 
headaches and distortion of vision, whereas adults present with gait 
disturbances and sensory polyneuropathy (Hakonen et al., 2005). Common 
symptoms in the early stages of disease are ataxia, neuropathy and lack or 
decrease in the tendon reflexes in lower limbs. Later, involuntary 
movements, dysarthria, dysphagia, nystagmus, psychiatric symptoms 
(depression, anxiety and hallucinations) and cognitive retardation may also 
be present. Epileptic seizures are prevalent, but not with every patient. In 
particular, adult-onset MIRAS may not cause epilepsy. Epileptic seizures are 
usually treatment resistant, may require general anesthesia and usually are 
the prelude to the patients’ demise. Epilepsy presents a clinical challenge, as 
sodium valproate, a common anticonvulsant, is toxic to liver for patients with 
POLG1 mutations and may lead to acute liver failure and ultimately liver 
transplantation (Ferrari et al., 2005; Tzoulis et al., 2006). In summary, a 
typical MIRAS patient has an onset in the third decade of life, with sensory 
polyneuropathy or gait disturbances and later progressive ataxia. Later, the 
patient may develop epilepsy. However, the clinical phenotype is highly 
variable. At the moment, no animal models of MIRAS have been published. 
 
A  surprising  feature  of  MIRAS is  that  it  does  not  necessarily  exhibit  the  
typical findings for mitochondrial disease: serum lactate is normal (except in 
some juvenile-onset cases) and muscle biopsy samples do not always show 
mtDNA  deletions  or  depletion  (Hakonen  et  al.,  2005;  Van  Goethem  et  al.,  
2004). A minor amount of COX negative fibers can be, however, seen in the 
muscle biopsy samples. Patients might have an increase in serum pyruvate. 
Nerve biopsy samples from the sural  nerve show a drastic  decrease in large 
myelinated fibers. In electroneuromyography, MIRAS patients have a clear 
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sensory axonal polyneuropathy, with a slight motor component. In the early 
stages of MIRAS, patients may not have any changes in their brain magnetic 
resonance imaging (MRI). When the disease progresses, the patients’ brains 
start to show bilateral cerebellar white matter changes in brain MRI, changes 
in basal ganglia, white matter changes and generalized brain atrophy.  
4.13.2 ALPERS’ SYNDROME  
 
Alpers’ syndrome is the most severe manifestation of POLG1 defects (Ferrari 
et al., 2005; Naviaux and Nguyen, 2004; Naviaux and Nguyen, 2005; 
Nguyen et al., 2005). Alpers’ syndrome is a recessive disease, caused by 
several different homozygous or compound heterozygous POLG1 mutations, 
c. 1399G?A,  leading  to  p.Ala467Thr  amino  acid  change,  being  the  most  
common and c. 2243G?C in cis with c.3428A?G, leading to  p.Trp748Ser + 
p.Glu1143Gly  amino  acids  changes  (in  other  words,  the  same  mutation  as  
found in MIRAS, thus underlining the heterogeneity of clinical  
manifestations in POLG1 diseases) being the second most common (Figure 5) 
(Tang et al., 2011). Some MIRAS patients are compound heterozygous for c. 
2243G?C in cis with c.3428A?G and c. 1399G?A mutations.  
 
Alpers’ syndrome is an autosomal recessive disease, with onset in early 
infancy  or  childhood,  usually  before  five  years  of  age  (Ferrari  et  al.,  2005;  
Isohanni et al., 2011; Naviaux and Nguyen, 2004). Alpers’ syndrome is 
characterized by four symptoms: psychomotor retardation, refractory 
epileptic seizures, cortical blindness and liver disease with micronodular 
cirrhosis (Table 1). Liver involvement is not always present (Huttenlocher et 
al., 1976). The infants are born healthy and the very first developmental 
milestones are normal. Often, the disease onset is after febrile illness, such as 
otitis media or diarrhea. In most cases, however, the presenting symptom is 
epileptic seizure. Other clinical symptoms that may develop are 
encephalopathy, ataxia, hypotonia and occasional elevation in serum lactate. 
From the onset of the disease, the symptoms and epileptic seizures become 
more  severe,  acute  liver  failure  develops,  which  leads  to  the  patients  death  
within a couple of years.  
 
mtDNA  depletion  and  respiratory  chain  complex  deficiency  may  be  
present, but not necessarily (de Vries et al., 2007; Isohanni et al., 2011). Also, 
muscle biopsy samples can lack any findings suggesting mitochondrial 
disease (Isohanni et al., 2011). The patients may have changes in brain MRI, 
but usually at the time of onset the MRI does not show any abnormalities. In 
the later course of the disease, cortical and hippocampal atrophy may be 
present, as well as focal lesions (Isohanni et al., 2011). 
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In post-mortem pathological examination, the patients have cerebellar 
atrophy, with patchy dropout of Purkinje cells (Ferrari et al., 2005; Naviaux 
and Nguyen, 2004). They also have atrophy of the cerebral cortex, visual 
cortex and occipital cortex. Also, the patients have neuronal loss in the basal 
ganglia, thalamus and hippocampi (Isohanni et al., 2011). In the liver, 
micronodular  cirrhosis,  hepatocyte  dropout,  microvesicular  fat  and  bile  
ductural proliferation is seen. 
 
The biochemical effect of several different amino acid changes, connected 
to  Alpers’  syndrome,  has  been  studied  (Chan  et  al.,  2005;  Luoma  et  al.,  
2005). Luoma and co-workers described the effect of p.Ala467Thr, p. 
Arg627Gln, p. Arg627Trp, p. Gln1236His and p. Arg627Gln + p. Gln1236His 
amino acid changes. Later, Chan and co-workers studied the effect of POLG1 
p.Ala467Thr.  The  amino  acid  changes  Luoma  and  co-workers  studied  were  
chosen because they were found in a family with ataxia-myopathy syndrome. 
The most severely affected member of the family had mutations leading to 
p.Ala467Thr, p. Arg627Gln and p. Gln1236His amino acid changes. Both 
studies found that the intrinsic polymerase activity and processivity of the 
p.Ala467Thr POLG1 were diminished (Chan et al., 2005; Luoma et al., 2005). 
Also, the interaction with the accessory subunit POLG2 and the ability of 
POLG2 to stimulate the function of the catalytic core was depleted. Although 
the results were similar, there were clear differences in the severity of the 
phenotype: Chan et al reported an almost complete lack of activity, whereas 
Luoma and co-workers described an enzyme that is clearly affected but 
partially functional. Luoma and co-workers described also p. Arg627Gln and 
p. Arg627Trp POLG1 enzymes, which did not exhibit a clear biochemical 
phenotype, whereas p. Gln1236His had higher enzymatic activity than the 
wild  type  enzyme  (Luoma  et  al.,  2005).  No  animal  models  of  Alpers’  
syndrome have been published. 
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Table 1. Comparison of mitochondrial ataxias. + present, - absent, ? unknown, RRF 
Ragged red fibers, COX- Cytochrome c oxidase deficient fibers 
 
 
  
 MIRAS Alpers’ 
Age of Onset 5-50 yrs 0-4 yrs 
Presenting 
symptom 
Gait disturbances / 
Epilepsy 
Intractable epilepsy, 
hypotonia 
Babinski sign -/+ ? 
Deep tendon 
reflexes 
- - 
Epilepsy +/- + 
Nystagmus +/- ? 
Dysarthria + - 
Dysphagia +/- ? 
Hearing loss - - 
Psychiatric 
symptoms 
Depression, anxiety, 
paranoia 
- 
Cognition Cognitive defects 
 
? 
Sensation Decreased for joint 
position, vibration 
? 
Neuropathy Mostly sensory, small 
motor component 
occasionally 
? 
Ophthalmoplegia +/- - 
Muscle mtDNA Few or no COX-
negative fibers. Small 
amount of multiple 
mtDNA deletions, 
occasional mild 
depletion 
mtDNA depletion 
 
References (Rantamäki et al., 
2001; Van Goethem et 
al., 2004) 
 
 
(Huttenlocher et al., 1976; 
Naviaux and Nguyen, 2004) 
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4.13.3 SENSORY ATAXIC NEUROPATHY, DYSARTHRIA AND 
OPHTHALMOPARESIS 
 
Sensory ataxic neuropathy, dysarthria and ophthalmoparesis (SANDO) is a 
mitochondrial ataxia, caused by several different mutations in POLG1 (Fadic 
et al., 1997). c. 1399G?A and c. 2243G?C mutations in POLG1 are the most 
IOSCA SANDO ARSACS Friedreich’s 
0-3 yrs ~20 yrs 1 yrs 10-51 yrs 
Hypotonia, 
athetosis 
Gait 
disturbances 
Ataxia, Pyramidal 
tract symptoms 
Ataxia 
+ - + + 
- - Ankle – 
 
- 
+ - - - 
- - + + 
- - + + 
- ? ? ? 
+ + ? - 
- Depression, 
bipolar 
- - 
Psychomotor 
retardation 
Cognitive 
defects 
Lower IQ ? 
Proprioception, 
tactile decreased 
Joint, vibration 
decreased 
Joint, vibration 
decreased 
Joint, vibration 
decreased 
Sensory axonal 
 
 
 Sensory axonal Sensory axonal 
- + - - 
Normal 
 
 
 
 
 
RRF, COX-, 
mtDNA 
deletions 
Normal Normal 
(Koskinen et al., 
1994a; Koskinen et 
al., 1994b) 
(Fadic et al., 
1997; Mancuso 
et al., 2004; Van 
Goethem et al., 
2003) 
(Bouchard et al., 
1978) 
(De Michele et 
al., 1994; 
Harding, 1981) 
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common mutations (Schulte et al., 2009). Clinically, SANDO is closely 
related to late-onset MIRAS: the disease onset is around 20 years of age 
orlater and the presenting symptom is weakness in lower limbs or gait 
disturbances (Table 1) (Fadic et al., 1997; Mancuso et al., 2004; Van 
Goethem et al., 2003). Additionally, ataxia, dysarthria, neuropathy, external 
ophthalmoplegia, ptosis, lack of deep tendon reflexes, diminished vibration 
and  position  sense  may  also  be  present.  In  comparison  to  MIRAS,  epilepsy  
has  not  been  reported  in  SANDO and muscle  atrophy  is  a  more  prominent  
feature. The disease progression is steady and leads to death of patients in 
their sixth decade of life. The most common cause of death is respiratory 
failure, again a clearly different feature from MIRAS.  Laboratory 
examinations do not provide any insight into the diagnosis: serum lactate 
and creatine kinase are normal or occasionally mildly elevated. Muscle 
biopsy samples have varying findings: some patients have ragged red fibers 
(RRF, muscle fibers which have accumulated abnormal mitochondria), and 
multiple  mtDNA  deletions,  whereas  some  do  not.  In  brain  MRI,  signs  of  
thalamic lesions and brain stem atrophy may be present. No animal models 
of SANDO have been published. 
4.13.4 PEO WITH PARKINSONISM 
 
POLG1 mutations  cause  multiple  different  syndromes,  one  of  which  is  
autosomal dominant PEO with parkinsonism (POLG1-PD) (Luoma et al., 
2004).  POLG1-PD has typical features for PEO: onset in 20-30’s with 
external ophthalmoplegia, ptosis and possibly sensory polyneuropathy 
(Chalmers et al., 1996; Checcarelli et al., 1994; Luoma et al., 2004; Moslemi 
et al., 1999; Siciliano et al., 2001). Parkinsonian features develop soon after 
or later, usually before the sixth decade. Tremor, rigidity and hypokinesia can 
be unilateral or bilateral, again different from idiopathic PD. Parkinsonian 
features develop slowly and show a good response to levodopa treatment.  
Usually, no Lewy bodies or ?-synuclein pathology are found, although some  
cases have been described in which Lewy bodies are found in substantia 
nigra (SN) and adjacent structures (Betts-Henderson et al., 2009; Moslemi et 
al., 1999). Otherwise, the neuropathological changes are similar to other 
POLG1 syndromes: sensory areas of spinal cord, cerebellum and brain stem 
show extensive neuronal death. It should also be noted that two case reports 
have been published, in which C10ORF2 mutation c. 1121G?A caused PEO 
with parkinsonism (Baloh et al., 2007; Vandenberghe et al., 2009). 
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4.14 OTHER CAUSES OF MITOCHONDRIAL ATAXIA 
4.14.1 INFANTILE-ONSET SPINOCEREBELLAR ATAXIA 
 
Infantile-onset spinocerebellar ataxia, IOSCA, is a progressive ataxia 
syndrome originally known as OHAHA (ophthalmoplegia, hypotonia, ataxia, 
hypacusis and athetosis) (Koskinen et al., 1994b). IOSCA is part of the 
Finnish disease heritage, with no patients elsewhere. IOSCA is caused by a 
mutation in mitochondrial DNA helicase, TWINKLE (encoded by C10ORF2). 
Two  mutations  are  found:  recessive  c.  1523  A?G and compound 
heterozygous c. 1523 A?G with c.952 G?A, leading to p. Tyr508Cys and p. 
Tyr508Cys + p. Ala318Thr amino acid changes, respectively (Hakonen et al., 
2007b; Nikali et al., 2005).  
 
The onset  of  IOSCA is  early in life,  after  an uneventful  birth and normal 
first milestones, at latest at the age of one and half years. (Table 1) (Koskinen 
et al., 1994a; Koskinen et al., 1994b). Again, as in Alpers’ syndrome, the first 
symptoms develop slowly or more quickly during febrile disease. The 
presenting symptoms are muscular hypotonia, ataxia and athetosis, or slowly 
progressing gait disturbances. The symptoms develop into ophthalmoplegia, 
optic atrophy and rapidly progressing deafness, which reaches almost 
complete deafness before the age of seven years. Patients have neuropathy 
and  their  muscles  in  lower  limbs  become atrophied.  Some patients  learn  to  
walk with support, whereas some do not. The cognitive capacity of the 
patients  is  normal,  but  during  the  progression  of  disease  becomes  more  
limited. Almost all patients develop epilepsy, which is usually the cause 
leading to their demise. The epilepsy, like in other mitochondrial diseases, is 
severe and hard to treat. Life expectancy may be limited, although some 
patients are still alive in their 50’s. 
 
Laboratory examinations do not provide any relevant information for 
diagnosis. In electroneuromyography patients have sensory axonal 
neuropathy. Brain MRI is normal in the first stages of the disease but during 
epileptic seizures, stroke-like episodic changes can be seen (Koskinen et al., 
1995; Lonnqvist et al., 2009). Patients’ muscle biopsy samples are also 
normal  and  they  have  no  mtDNA  deletions  or  disruptions  in  respiratory  
chain components (Nikali et al., 2005). In liver and brain tissue samples 
(cerebral cortex and cerebellum) however, patients have tissue specific 
mtDNA depletion and CI and CIV deficiency (Hakonen et al., 2008b). 
 
In neuropathological examination, the patients have moderate atrophy of 
cerebellum and brain stem (Hakonen et al., 2007b; Lönnqvist et al., 1998). In 
spinal cord, they have severe atrophy of posterior aspects of the spinal cord, 
especially posterior spinocerebellar columns and spinal ganglions. In the 
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cerebellum, loss of Purkinje cells and severe destruction of the nucleus 
dentatus are the most prominent findings. In the mesencephalon, loss of 
neurons in SN is found. 
 
The  biochemical  effect  of  p.  Tyr508Cys  amino  acid  change  has  been  
studied with in vitro assays (Hakonen et al., 2008b). The p. Tyr508Cys 
TWINKLE had higher helicase unwinding activity than the wild-type enzyme, 
but overexpression of p. Tyr508Cys TWINKLE did show a minor increase in 
mtDNA copy number. However, no catalytic defect was detected. Currently 
no animal models of IOSCA exist.  
4.14.2 FRIEDREICH’S ATAXIA 
 
Friedreich’s ataxia is an autosomal recessive ataxia syndrome, which is 
caused by mutations in the FXN gene  (Campuzano  et  al.,  1996).  The  most  
common  mutation  is  a  homozygous  expansion  of  a  GAA-repeat  in  the  first  
intron of FXN, which accounts for 95% of cases. In a small minority of cases, 
the GAA-repeat is compound heterozygous with a point mutation in FXN 
(Cossee et al., 1999). The age of onset is in most cases in puberty, although 
the disease may develop as early as two years of age or later, at the age of 50 
(Table 1) (De Michele et al., 1994; Harding, 1981). The presenting symptoms 
are gait disturbances and ataxia, which develop into tremor and loss of 
balance. The patients lose their ability to walk without support usually within 
10-15 years. Also, dysarthria and dysphagia develop. Patients have 
hypertrophic cardiomyopathy and repolarisation disturbances in heart, 
although this does not cause clinical symptoms in most cases (Casazza and 
Morpurgo, 1996). Neither mtDNA abnormalities nor COX deficient muscle 
fibers have been found. Neuropathological findings resemble other 
mitochondrial ataxias: axonal sensory polyneuropathy, atrophic posterior 
columns  in  spinal  cord,  as  well  as  spinocerebellar  tracts  [Reviewed  in  
(Koeppen, 2011)]. Nucleus dentatus is severely affected in cerebellum, but 
cerebellar  cortex  or  Purkinje  cells  are  mildly  affected.  Motor  tracts  are  not  
affected in early phases of the disease, but later show some atrophy, probably 
due to the dying-back process. Several different mouse models of Friedreich’s 
ataxia have been produced: complete knock-out of FXN is embryonic lethal, 
whereas knock-in models with variable GAA-repeat expansions lead to 
decrease in FXN expression  (Cossee  et  al.,  2000;  Miranda  et  al.,  2002).  
Time-course analysis of pathological changes in a specific neuronal knock-
out of FXN has shown that the damage in distal root ganglia is the primary 
insult, which leads to degeneration in Clarke’s column and other areas of 
spinal cord and brain (Simon et al., 2004). Friedreich’s ataxia is an extremely 
rare disease in Finland, with just six reported patients (Juvonen et al., 2002). 
However, Friedreich’s ataxia is more common elsewhere. 
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4.14.3 AUTOSOMAL RECESSIVE SPASTIC ATAXIA OF CHARLEVOIX-
SAGUENAY 
 
Autosomal recessive spastic ataxia of Charlevoix-Saguenay (ARSACS) was 
first described in French-Canadian regions of Quebec (Bouchard et al., 1978). 
ARSACS is a slowly progressing ataxia syndrome, with dysarthria, spasticity, 
wasting of distal muscles, nystagmus and mitral valve prolapse (Table 1). 
ARSACS is not only found in Quebec, but also in Italy and Japan (Criscuolo 
et al., 2004; Grieco et al., 2004; Ogawa et al., 2004). The disease onset is in 
early childhood, but late-onset disease has also been described. The patients 
rarely walk at all. Despite these features, the disease progression is slow but 
still leads to reduced life expectancy. ARSACS is caused by mutations in the 
SACS gene  and  although  a  variety  of  mutations  in  this  gene  have  been  
described, no definite correlations between genotype and phenotype exist  
(Engert et al., 2000). SACSIN, encoded by SACS, is a protein that affects 
mitochondrial dynamics: knock-out and knock-down of SACS in mice leads 
to a more interconnected mitochondrial network, diminished membrane 
potential and ultimately lack of dendrites (Girard et al., 2012). Also, SACS 
knock-out  mice  are  born  normal  but  later  develop  a  progressive  loss  of  
Purkinje  cells  in  the  cerebellum.  Neuropathological  findings  in  humans  are  
similar: a progressive loss of Purkinje cells and cerebellar atrophy are the 
most prominent findings [Reviewed in (Bouchard et al., 1998)]. Although 
SACSIN is a mitochondrial protein, no disruption in respiratory chain or 
mtDNA has been described. 
 
4.15 PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA 
 
Progressive external ophthalmoplegia (PEO) is a classical mitochondrial 
syndrome, which is characterized by diminished eye movements and ptosis.   
PEO is a feature in multiple mitochondrial disorders, with many different 
causes (Table 2). Patients develop PEO usually between 20-40 years of age. 
Together with ptosis and sensory polyneuropathy, diminished eye 
movements are usually the presenting symptom. The variety of other clinical 
symptoms connected to PEO is diverse: ataxia, myopathy, psychiatric 
disorders, premature menopause, primary ovarian failure, hypogonadism, 
parkinsonism and a plethora of other symptoms have been reported (Bohlega 
et al., 1996; Lundberg, 1962; Melberg et al., 1996; Moraes et al., 1989; 
Suomalainen et al., 1992a; Suomalainen et al., 1997; Suomalainen et al., 
1992b; Van Goethem et al., 1997). When mitochondrial disease is suspected, 
histological analysis of a muscle biopsy sample is considered to be the gold 
standard for diagnosis, before molecular diagnosis. In PEO, muscle biopsy 
samples have typical changes for mitochondrial disease: RRFs, COX negative 
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fibers and decreased enzyme activity for respiratory chain enzymes. 
Mitochondrial DNA deletions, depletion or point mutations may be found in 
muscle samples. The deletions can be either multiple deletions in muscle or 
single large deletions in all tissues (Bohlega et al., 1996; Holt et al., 1988; 
Moraes  et  al.,  1989;  Zeviani  et  al.,  1989).  PEO  with  single  deletions  is  
sporadic  whereas  PEO  with  multiple  mtDNA  deletions  is  caused  by  
autosomal genes, in  a recessive or dominant manner (arPEO, adPEO). 
 
The  last  decade  has  opened  the  molecular  basis  of  PEO  and  revealed  
several different modes of transmission and disease loci: mendelian or 
maternal inheritance, autosomal recessive and dominant PEO, point 
mutations and single deletions in mtDNA, and mutations in nuclear genes 
have all been reported (Hudson et al., 2008; Kaukonen et al., 2000; Longley 
et  al.,  2006; Moraes et  al.,  1989; Spelbrink et  al.,  2001;  Takata et  al.,  2011;  
Tyynismaa et al., 2012; Tyynismaa et al., 2009; Van Goethem et al., 2001; 
Verma et al., 1996). Mutations in ANT1 (HUGO name SLC25A4), Twinkle 
(C10Orf2), POLG1, POLG2, TK2, OPA1 and RRM2B are all connected to 
PEO. However, mutations in POLG1 and TK2 are  the  only  known  cause  of  
arPEO.  
Table 2. Comparison of PEO syndromes.  Mitochondrial encephalopathy with lactic 
acidosis and stroke-like episodes (MELAS), autosomal dominant / recessive progressive 
external ophthalmoplegia (adPEO/arPEO), mitochondrial neurogastrointestinal 
encephalomyopathy (MNGIE). 
  
  47
 MELAS Kearns-Sayre 
Syndrome, 
sporadic PEO 
adPEO/arPEO MNGIE 
Genetic cause mtDNA 
m.3243A?G,  
MTTL1 gene 
mtDNA deletion POLG1,POLG2, 
Twinkle, 
RRM2B, 
OPA1,TK2, 
ANT1 
TYMP and 
RRM2B 
mutations 
mtDNA 
rearrangements 
- Single large 
mtDNA deletion 
Multiple 
mtDNA 
deletions 
mtDNA depletion 
and deletions 
Age of Onset Any age Early teenage Early adulthood Juvenile 
Typical 
symptoms 
Epileptic sei-
zures, stroke-
like episodes, 
headache, 
PEO, 
diabetes, 
deafness 
Retinitis 
pigmentosa, 
dilated 
cardiomyopathy, 
PEO 
Ptosis, 
myopathy, PEO, 
exercise 
intolerance 
Gastrointestinal 
dysfunction, 
muscle atrophy, 
PEO, nausea  
Other 
symptoms 
Exercise 
intolerance, 
encephalo-
pathy, lactic 
acidosis 
Cardiac 
conduction 
blocks, ataxia, 
hearing loss, 
dementia 
Polyneuro-
pathy, 
parkinsonism, 
depression 
Polyneuropathy, 
leukoencephalo-
pathy, cachexia 
References (Goto et al., 
1990; 
Pavlakis et 
al., 1984) 
(Kearns, 1965; 
Lestienne and 
Ponsot, 1988) 
(Moraes et al., 
1989; 
Suomalainen et 
al., 1992a; 
Suomalainen et 
al., 1997; Van 
Goethem et al., 
2001; Zeviani et 
al., 1989) 
(Bardosi et al., 
1987; Hirano et 
al., 1994; 
Taanman et al., 
2009) 
4.16 MITOCHONDRIA AND PARKINSONISM 
Parkinson’s disease (PD) is the second most common neurodegenerative 
disease  in  the  world,  with  a  prevalence  of  166/100000  in  Finland.  PD  is  
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characterized by three clinical symptoms: rigidity, tremor and hypokinesia. 
These  symptoms  are  the  main  motor  symptoms  associated  with  PD.  These  
motor symptoms develop quite late in the course of disease, delaying the 
diagnosis. Non-motor symptoms, such as disturbances of sleep, 
incontinence, constipation and impaired ability to smell, develop earlier but 
as they are rather unspecific they do not help in the diagnosis. The median 
age  of  onset  for  PD  is  usually  in  the  sixth  decade  of  life  (Table  3).  No  
diagnostic laboratory tests or imaging examinations exist and the diagnosis is 
based on the clinical signs. Single-photon emission computed tomography 
and positron emission tomography may aid in the diagnosis, but otherwise 
laboratory  examinations  and  imaging  studies  are  done  to  rule  our  other  
possible causes for the symptoms. The gold standard for PD diagnosis is 
found  post  mortem:  lack  of  neurons  in  the  SN  and  more  specifically,  Lewy  
bodies  in  the  remaining  neurons  of  the  SN.  Lewy  bodies  are  protein  
aggregates, which are composed mainly of misfolded alpha-synuclein. When 
motor symptoms develop, about 60% of SN dopaminergic neurons have died. 
This  causes  a  problem for  both  diagnosis  and  treatment  of  the  disease:  the  
diagnosis is made late in the course of the disease and the treatment is only 
to relieve symptoms, not to reverse the course of the disease.  
 
During the last decades there has been an enormous effort to understand 
the  pathogenesis  of  PD.  Since  the  first  description  of  an  Italian  family  with  
hereditary PD, caused by mutations in SNCA, several loci have been 
described (Lill et al., 2012; Polymeropoulos et al., 1997; Saad et al., 2011; 
Simon-Sanchez et  al.,  2009).  Currently 20 different loci,  which cause either 
recessive or dominant PD or alter the risk of sporadic PD, have been 
confirmed. These loci are connected to a heterogeneous set of pathways. 
However, some noteworthy pathways have emerged: The ?-synuclein 
pathway, the leucine-rich repeat kinase 2 (LRRK2) pathway and the 
mitochondrial  pathway,  consisting  of  PD  caused  by  mutations  in  PINK1, 
Parkin, DJ-1 and POLG1. 
 
Mitochondrial dysfunction as a cause of PD was proposed long before the 
modern age of genetics. PD patients have CI deficiency in multiple tissues: 
platelets, muscle, lymphocytes and SN (Bindoff et al., 1989; Haas et al., 1995; 
Krige et al., 1992; Parker et al., 1989; Schapira et al., 1989; Yoshino et al., 
1992). Mitochondrial toxins and CI inhibitors rotenone and 1-methyl-4-
phenyl-1,2,3,6-tetrahydropyridine (MPTP), can cause PD-like disease 
(Betarbet et al., 2000; Langston et al., 1983; Langston and Ballard, 1983). 
These  substrates  are  also  widely  used  to  produce  animal  models  for  PD.  It  
was therefore not a surprise when PARK2, PARK6 and PARK7 loci, causing 
autosomal recessive juvenile Parkinson’s disease (ARJPD) were linked to 
mitochondrial function. 
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ARJPD is a subgroup of hereditary PD, which is characterized by early 
onset between 20-40 years of age, bilateral symptoms, slow disease 
progression and critically the lack of Lewy bodies (Table 3) (Albanese et al., 
2005; Dekker et al., 2003; Ibáñez et al., 2006; Lücking et al., 2000; Mori et 
al., 1998; van de Warrenburg et al., 2001). ARJPD is caused by mutations in 
PARK2, encoding parkin. (Kitada et al., 1998) Shortly after PARK2 mutations 
were described, mutations in DJ1 and PINK1 were reported to cause similar 
early-onset, recessive PD (Bonifati et al., 2003; Valente et al., 2004). In 
cultured cells and D. melanogaster,  Parkin  and  PINK1  have  been  found  to  
function in the same mitophagy pathway, as described in Figure 2. Parkin 
overexpression is able to rescue the PINK1 mitochondrial phenotype, but not 
reverse,  supporting  the  function  in  the  same pathway  even  further  (Park  et  
al., 2006). The function of DJ-1 is not well understood, but it relocates from 
cytosol to mitochondria under oxidative conditions and the loss of DJ-1 leads 
to mitochondrial fragmentation and impaired mitophagy (Canet-Aviles et al., 
2004; Irrcher et al., 2010; Junn et al., 2009; Krebiehl et al., 2010; Thomas et 
al., 2011). Overexpression of PINK1 and PARKIN rescues the structural 
abnormality caused by DJ-1 deficiency, suggesting that they all operate in the 
same pathway (Irrcher et al., 2010). 
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Table 3. Comparison of PD symptoms. PD Parkinson’s disease, ARJPD Autosomal 
recessive juvenile Parkinson’s disease, POLG1-PD PEO with parkinsonism,SN substantia 
nigra, ANS: autonomic nervous system 
 
 Idiopathic PD ARJPD POLG1-PD 
Age of Onset Median 60 yrs 20-40 yrs 30-60 yrs 
Lewy bodies in SN Yes, prevalent No Occasionally in 
SN 
Bilateral / Unilateral 
onset of symptoms 
Unilateral Bilateral Both 
ANS symptoms Yes No Not characterized 
Levodopa response Initially good Well preserved Well preserved 
Parkinsonism 
progression 
Quick Slowly 
progressive 
Slowly progressive 
Cognitive defects Commonly 
dementia 
No Occasionally 
References Reviewed in (Lees 
et al., 2009) 
(Albanese et al., 
2005; Dekker et 
al., 2003; Ibáñez 
et al., 2006; 
Lücking et al., 
2000; Mori et 
al., 1998; van de 
Warrenburg et 
al., 2001) 
(Betts-Henderson 
et al., 2009; 
Luoma et al., 
2004) 
 
The function of ?-synuclein has been and is still largely unknown. 
However, strong evidence suggests that ?-synuclein has a mitochondrial-
connected  function  [For  a  review (Protter  et  al.,  2012)].  It  has  a  cryptic  N-
terminal mitochondrial targeting signal and is able to relocate from the 
cytosol  to  the  mitochondrial  inner  membrane  (Devi  et  al.,  2008;  Parihar  et  
al., 2008). The exact signal that triggers the relocalization is not known. 
Alpha-synuclein alters the mitochondrial fusion / fission cycle and thus the 
mitochondrial morphology in dopaminergic human SH-SY5Y neuroblastoma 
cells and HeLa cells: overexpression of ?-synuclein leads to decreased fusion 
  51
events and fragmentation whereas knockdown of ?-synuclein causes 
mitochondrial elongation (Kamp et al., 2010; Nakamura et al., 2011). The 
fission inducing function of ?-synuclein is independent from the native 
fission machinery (Nakamura et al., 2011). In addition, the PD associated, p. 
Ala53Thr  ?-synuclein  induces  mitophagy  (Choubey  et  al.,  2011).   Alpha-
synuclein  knock-out  mice  also  exhibit  resistance  to  the  CI  inhibitor  MPTP  
(Dauer et al., 2002). 
 
LRRK2 mutations are a common cause of both autosomal-dominant and 
sporadic  PD  (Kachergus  et  al.,  2005;  Lill  et  al.,  2012).  However,  the  
penetrance of the LRRK2 mutations and clinical symptoms show more 
variability than a-synuclein (Kachergus et al., 2005; Papapetropoulos et al., 
2006). LRRK2 mutations have also been connected to other 
neurodegenerative phenotypes, such as amyotrophy, Meige dystonia 
syndrome and supranuclear gaze palsy (Chen-Plotkin et al., 2008; Ross et al., 
2006a; Ross et al., 2006b). Like ?-synuclein, the function of LRRK2 has 
remained elusive. A function in lysosomal trafficking has been suggested. 
LRRK2 is  present  mainly  in  the  cytosol,  but  also  in  the  outer  membrane  of  
mitochondria (Biskup et al., 2006). In C. elegans and D. melanogaster, 
LRRK2 has been shown to alter the susceptibility to rotenone induced CI 
deficiency, thus strengthening the mitochondrial link (Ng et al., 2009; Saha 
et al., 2009). Niu and Wang have recently demonstrated an even more direct 
connection  of  LRRK2  and  mitochondrial  function,  using  human  cerebral  
cortex neurons, dopaminergic SH-SY5Y cells and rat primary neurons (Niu et 
al., 2012; Wang et al., 2012). They show that LRRK2 disrupts mitochondrial 
dynamics via the dynamin like GTPase DLP1, causing mitochondrial 
fragmentation. The effect required for the kinase-function of LRRK2 and the 
commonly altered p. Gly2019Ser and p. Arg1441Cys residues had even 
stronger phenotypes. The current data from PINK1, DJ-1, PARKIN, ? -
synuclein  and  LRRK2  related  PD  show  a  possible  role  for  mitochondrial  
dynamics in PD pathogenesis, not just limited to ARJPD. 
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5 AIMS OF THE STUDY 
The work for this study began in 2003, with a specific focus on the diseases 
caused by POLG malfunction. Two particular findings were the basis for this 
thesis: the recent characterization of MIRAS by our research group and 
collaborators and the role of POLG1 mutations in both idiopathic and PEO-
linked parkinsonism. 
 
The questions we wanted to answer in this study were: 
 
? Why only some patients with dysfunctional mtDNA replisome develop 
parkinsonism and others do not? Could this be explained by 
mesencephalonic changes or dysfunctional respiratory chain? 
? Is it possible that the high carrier frequency of the MIRAS disease 
allele in Finland and other countries could cause MIRAS to manifest 
with a pseudo-dominant inheritance? 
? Can we explain the clinical heterogeneity of MIRAS with the 
biochemical properties of p. Thr748Ser POLG1? 
? Can we utilize existing biochemical data of POLG1 amino acid changes 
and the crystal structure of POLG1 to assess the structure-functional 
relationship for recessive POLG1 disease mutations? 
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6 MATERIALS AND METHODS 
The methods used in this study are summarized briefly here and described in 
more detail in the original publications (I-IV). 
 
This study was approved by the ethical review board of Helsinki 
University Central Hospital (Dnro: 43/13/3/04/2008 and 432/E9/2007) 
and the subjects or their relatives gave their written informed consent. 
6.1 PATIENTS AND CONTROLS (I, II) 
We  collected  autopsy  samples  from  patients  with  mtDNA  maintenance  
disorders. MIRAS (n=3) and POLG1-PEO-parkinsonism (n=2) with POLG1 
mutations  were  compared  to  IOSCA  (n=1)  and  adPEO  (n=1),  the  latter  not  
associated with parkinsonism. As controls we had samples from subjects, 
who died of non-neurological causes (n=3).  
6.1.1 MIRAS PATIENTS 
 
The presenting symptom for all MIRAS patients (n=3) was gait disturbance, 
but the age of onset varied: from childhood to early thirties. All patients 
developed ataxia, sensory polyneuropathy and epilepsy. Depression and 
anxiety were also present in all patients. All MIRAS patients were 
homozygous for mutations in POLG1, c. 2243G?C in cis with c.3428A?G, 
leading to p.Trp748Ser + p.Glu1143Gly amino acid changes. 
6.1.2 POLG1-PD PATIENTS 
 
Both patients developed typical signs of PEO in their third decade of life: 
ptosis, external ophthalmoplegia and sensory polyneuropathy. Later, they 
developed difficulties in swallowing. They also had a decrease in the strength 
of his neck muscles and one patient required a mechanical support. The ages 
for diagnosis of PD were 46 and 57 years of age. The presenting symptom of 
parkinsonism was rigidity and lack of associated movements in one patient 
and wide, unsteady gait and hypokinesia in another. Both were responsive to 
levodopa and although the parkinsonism progressed steadily in both 
patients, the course of the disease was mild. POLG1 was sequenced in both 
patients: P4 was homozygous for c. 1402A?G and c. 3316G?A, leading to p. 
Asn468Asp and p. Ala1105Thr amino acid changes. P5 was heterozygous for 
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c.2864A?G 13906C?T mutation in POLG1, resulting in p.Tyr955Cys amino 
acid change. 
 
6.2 MORPHOLOGICAL AND NEUROPATHOLOGICAL 
ANALYSIS (I, II) 
Neuropathological examination was performed according to standard clinical 
practice and autopsies were performed 4-72h post mortem. 
 
Neuropathological samples were studied after fixation in formalin 
embedding in paraffin. We used samples from brain, spinal cord and muscle 
from both patients and controls. We used 4-8 µm sections. We used 
hematoxylin-eosin and luxol fast blue-cresyl violet. In 
immunohistochemistry, we used various antibodies for: p62 (Clone D-3, 
Santa  Cruz,  CA,  US),  alpha  synuclein  (clone  42,  BD  Biosciences,  US),  TAU  
(Clone AT8, Innogenetics, Belgium), GFAP (MO761, 6F2; Dako Carpinteria, 
CA, US), SMI-311 (Sterberger Monoclonals Inc, Baltimore, MD, US) and AP-
2 (M-4403, Sigma, St. Louis, MO, US).  
 
In respiratory chain component immunohistochemistry we used 
antibodies against ND1 and AFG3L2 (Gift from Dr. Anne Lombes and Dr. 
Thomas Langer, respectively), NDUFS3 (MS110, Mitosciences, Eugene 
Oregon,  US),  NDUFA9  (MS  111,  Mitosciences)  of  CI,  70  kDa  Fp  subunit  
(MS204, Mitosciences) against CII, UQCRC2 (MS304, Mitosciences) against 
CIII and COXII (MS405, Mitosciences) against CIV. 
 
DAB was used as a visualization agent. The exact reaction conditions and 
antibody concentrations are described in articles  I and II. 
6.3 MTDNA ANALYSIS (I) 
6.3.1 MTDNA POINT MUTATION LOAD 
 
We extracted total DNA from muscle using standard laboratory methods. 
 
We used PCR to amplify parts of the mtDNA control region (D-loop) and 
cytochrome b gene  as  described  in  study  I.  The  amplified  products  were  
cloned  into  the  Zero  Blunt  TOPO  PCR  cloning  vector  (Invitrogen)  and  we  
extracted plasmid DNA from the samples. For cytochrome b gene 25 000 nt 
and for D-loop 20 000 nt were sequenced by Sanger sequencing, per patient. 
We used Sequencher (Gene Codes Corporation, Ann Arbor, MI, US) software 
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to analyse the sequences. Each mutation was counted once, to evaluate de 
novo mutagenesis and to rule out clonal expansion of the same mutation. 
6.3.2 MTDNA DELETIONS 
 
We used long-range PCR to amplify an 8.3 kb part of mtDNA, located 
between nucleotides 8232-16496. Muscle mtDNA (from total DNA) was used 
as a template and we used Expand Long Template PCR System (Roche) with 
buffer system I. The annealing temperature was set to 63°C and we used two 
different extension times, 8 and 3 minutes, to favour the amplification of 
deleted mtDNA molecules. As a control we used samples from a patient with 
multiple mtDNA deletions and a normal control. 
6.3.3 MTDNA LEVEL 
 
We amplified a part of the cytochrome b gene (mitochondrial gene target) 
and compared its amplification product with the nuclear gene encoding 
amyloid precursor protein (APP) using TaqMan real-time quantitative PCR 
system, to quantify the amount of mitochondrial DNA. Total muscle DNA 
was used as a template. The reactions were done in triplicates. We used ABI 
PRISM 7000 Sequence Detection System. We created a standard curve using 
known copy numbers of standard plasmids containing the CytB or APP gene 
targets, and subsequently, relative quantity of mtDNA to APP. 
6.4 POLG1 SEQUENCING (I) 
POLG1 mutations  were  screened  from  the  patients  by  traditional  Sanger  
sequencing. We analysed all exons of POLG1, as previously published (Van 
Goethem et al., 2001). 
6.5 PROTEIN PREPARATION (III) 
6.5.1 CONSTRUCTION OF RECOMBINANT BACULOVIRUSES 
 
We constructed baculovirus transfer vectors carrying POLG1 cDNAs with 
c.2243G?C nucleotide change using QuikChange mutagenesis with Pfu DNA 
polymerase (Stratagene, Santa Clara, CA, US). Transfer vectors were purified 
and baculoviruses prepared as previously (Wang and Kaguni, 1999). 
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6.5.2 PURIFICATION OF RECOMBINANT POLG1 
 
The method used has been described in detail (Luoma et al., 2005). In short, 
we infected Sf9 (Spodoptera frugiperda) insect cells with baculoviruses 
carrying mutant POLG1. Cells were collected, homogenized and centrifuged 
to extract the cytoplasmic soluble fraction (Fraction I). This fraction was 
loaded on a phosphocellulose column, which was washed with potassium 
phosphate buffer. The resulting fractions were analyzed for activity using 
standard polymerase assay with gapped dsDNA. Active fractions were pooled 
(Fraction II) and incubated with ammonium sulfate overnight, dialysed to an 
ionic strength of 300-400 mM KCl (Fraction IIb) and loaded to nickel-
nitrilotriacetic acid (Ni-NTA) resin. Again, active fractions were pooled 
(Fraction III) and loaded to glycerol gradients and centrifuged. Finally, the 
active fractions were pooled and stabilized by addition of glycerol to 45% 
(Fraction IV). Equivalent units of fraction IV enzyme were electrophoresed 
and stained using silver. The specific activity of the enzyme was measured 
using standard polymerase assay with gapped dsDNA. 
6.6 BIOCHEMICAL ANALYSIS OF POLG FUNCTION (III) 
6.6.1 MEASUREMENT OF DNA POLYMERASE ACTIVITY 
 
DNA polymerase activity was measured on (1) DNase I-activated calf thymus 
DNA, (2) singly-primed M13 DNA and (3) poly r(A)? oligo d(T). For steady 
state kinetic values, we used 5-400 nM of DNase I-activated calf thymus 
DNA or  0.125-8  µM singly-primed M13  DNA.  All  assays  were  done  at  least  
twice with duplicate samples. For stimulation assays, four-fold excess of 
recombinant POLG2 was added to reaction mixtures. With one unit of 
standard activity, we refer to the amount of protein that catalyses the 
incorporation of 1 nm of deoxynucleoside triphosphate into acid insoluble 
material in 60 min at 30 ?C using DNase I-activated calf thymus DNA as a 
substrate. 
6.6.2 DNA BINDING ASSAYS 
 
We  used  gel  electrophoretic  mobility-shift  assay  to  measure  DNA  binding  
affinity. We used singly-primed M13 DNA as a template, with 9 – 576 nmol 
of POLG1 and 4-fold molar excess of POLG2. The density of the distinct 
bands was analysed with ImageQuant software (version 5.2, GE Healthcare, 
Piscataway, New Jersey) and Kd values calculated with Origin 7.5 (OriginLab) 
from the fraction of DNA bound. At least two independent experiments were 
done, with duplicate samples per enzyme. 
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6.6.3 ANALYSIS OF PRODUCTS OF PROCESSIVE DNA SYNTHESIS 
 
We analysed the products of processive DNA synthesis by using singly-
primed M13 DNA as a template, 20 ng of POLG1 and 4-fold excess of POLG2. 
The density of the bands was determined by computer integration analysis 
using ImageQuant software (version 5.2, GE Healthcare). We normalised the 
density  of  the  bands  to  the  nucleotide  level  to  correct  for  the  uniform  
labelling of the DNA products and the DNA strand lengths are presented as 
average processed units (APU), in nucleotides.  
6.7 OVEREXPRESSION OF POLG1 IN CELLS (III) 
We produced four POLG1 cDNAs with PCR site-directed mutagenesis: wild 
type POLG1, c.2243G?C POLG1, c.3428A?G POLG1 and c.2243G?C 
together with c.3428A?G POLG1. Mutated PCR products were purified with 
DpnI restriction endonuclease (NEB), digested with EcoRI and BamRI 
restriction endonucleases and then gel purified. Blunt-ended POLG1 inserts 
were ligated into pBABEpuro vectors and verified with sequencing. These 
vectors were used to transfect retrovirus packaging cells of GP+E86 cell line. 
We used puromycin as a selection agent, collected the medium and infected a 
PA317 cell line with the medium. Again, puromycin was used as a selection 
agent and virus-containing medium from PA317 cells was collected. Finally 
human primary fibroblasts were transduced with this medium. Infected, 
POLG1 overexpressing cells were collected using standard trypsin-based 
method,  and  RNA  was  extracted  from  cells  with  Qiagen  RNeasy  Mini  Kit  
(Qiagen). After reverse transcription of RNA, we did the real-time 
quantitative PCR analysis of POLG1, C10ORF2 and, as an internal control, 
the beta actin gene ACTB using the TaqMan system (Invitrogen). 
 
6.8 PULSE LABELLING OF MITOCHONDRIAL 
TRANSLATION PRODUCTS (III) 
We studied the effect of overexpression of the above described mutant 
POLG1s in mitochondrial translation by first stopping the translation in cells, 
then labelling the cells with 35S, stopping the labelling with centrifugation, 
isolating mitochondria and loading sonicated products to gradient gels. 
These gels were fixed, dried and exposed to Phosphor Screen, as described by 
(Boulet et al., 1992). 
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6.9  PROTEIN MODELLING OF POLG (III, VI) 
We used VMD software to study the docking of DNA templates to POLG1 
(PDB entry 3IKM, chain A) (Humphrey et al., 1996). We collected all known 
Alpers’ disease mutations by using Human DNA Polymerase Gamma 
Mutation Database (http://tools.niehs.nih.gov/polg/). We collected a list of 
all POLG1 mutations linked to Alpers’ disease from the database and 
reviewed the references manually. 
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7 RESULTS AND DISCUSSION 
7.1 CLINICAL MANIFESTATIONS OF MIRAS (I, II) 
The  clinical  manifestation  of  MIRAS  is  not  homogeneous:  instead,  there  is  
great variability in almost all major features, such as age of onset, disease 
progression and epilepsy. However, no dominant inheritance of MIRAS has 
been described. Our MIRAS patient sample comprised a mother-son pair, 
both  with  a  MIRAS  phenotype,  raising  the  question  of  a  dominant  SCA-
disorder.  The  son  also  had  an  earlier  age  of  onset  for  the  symptoms,  
suggesting anticipation, but otherwise his disease progression resembled his 
mother’s. In addition, we examined a sporadic MIRAS patient. Both patients, 
mother and son, were homozygous for MIRAS mutations (c.2243G?C and c. 
3428A?G). This prompted us to examine POLG1 of the father, who was 
asymptomatic. He was a carrier of the MIRAS disease allele. The carrier 
frequency of this allele is high in Finland, Norway and Belgium and 
introduction  of  three  disease  alleles,  two  from  one  parent  and  one  from  
another, is a realistic possibility (Hakonen et al., 2007a; Hakonen et al., 
2005;  Van  Goethem  et  al.,  2003;  Winterthun  et  al.,  2005).   Hereditary  
ataxias with dominant inheritance are usually thought to be spinocerebellar 
ataxias. However, atypical features such as epilepsy should guide the 
clinician  to  consider  the  possibility  of  MIRAS.  Also,  in  countries  where  the  
carrier  frequency  of  the  MIRAS allele  is  high,  POLG1 should be considered 
even in the case of dominant inheritance. 
 
The clinical features of MIRAS in the mother and son suggested 
anticipation and we wanted to study if  it  was caused by mtDNA alterations.  
mtDNA is maternally inherited and possible transmission of mtDNA 
deletions or point mutations could explain the earlier onset of MIRAS in the 
son.  We examined  the  point  mutation  load  and  mtDNA copy  number  from 
these two MIRAS patients. Both patients had moderate mtDNA depletion, 
but no significant increase in point mutation load and no deletions in 
mtDNA. Although both patients shared some unique point mutations, we 
cannot conclude that mtDNA point mutation load would be a factor for the 
seemingly anticipatory clinical phenotype. 
 
7.2 NEUROPATHOLOGY OF POLG1-PD AND MIRAS 
PATIENTS (I, II) 
The clinical phenotypes of POLG1 mutation patients vary from late-onset 
PEO phenotypes to early-onset MIRAS with catastrophic epileptic seizures, 
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among several others manifestations. We did a complete neuropathological 
examination of several POLG1 patients,  in  order  to  understand  the  clinical  
manifestations and heterogeneity of the phenotypes. A specific area of 
interest was mesencephalon: POLG1-PD patients have PEO and 
parkinsonism and although sporadic reports of Twinkle mutation and 
MIRAS patients with parkinsonism exists, parkinsonism is not a common 
feature in patients with other alterations in mtDNA replication. Thus, we 
focused on the mesencephalic changes and asked if they could explain the 
parkinsonism. 
 
The neuropathological features of the patients are only briefly summarized 
here. The full description of patients can be found in the original articles. 
7.2.1 MIRAS 
 
Neuropathological findings of our MIRAS patients were similar: highly 
specific sensory nervous system manifestation. Peripheral nerves showed 
subtotal loss of large myelinated fibers; spinal cord had severe neuron loss in 
posterior spinocerebellar tracts and posterior columns and in cerebellum loss 
of Purkinje cells and atrophy of dentate nucleus. Inferior olives had neuron 
loss with spongiotic vacuolization in mediodorsal thalamic nucleus and 
parieto-occipital region of subcortical white matter in one patient. One 
patient had several COX negative fibers, whereas one patient did not have 
any changes suggesting mitochondrial disease in her muscle biopsy sample. 
The neuropathological findings were confined to the sensory and 
proprioception system, which is in line with the previously published 
neuropathological examinations of MIRAS (Rantamäki et al., 2001; Van 
Goethem  et  al.,  2004).  Both  patients  also  had  moderate  neuron  loss  in  the  
pars compacta of SN, especially in the dorsal tier, but no clinical sings of PD. 
They did not either have Lewy bodies in the SN or mesencephalon. In PD at 
least 60% of SN neurons need to die, before the PD motor symptoms develop 
[Reviewed in (Braak et al., 2004)]. We know that POLG1 patients with a 
catalytic deficiency may develop parkinsonism and a sporadic MIRAS patient 
has been described with late onset parkinsonism (Luoma et al., 2004; Remes 
et al., 2008). Our results suggest that although MIRAS patients have neuron 
loss in the substantia nigra, parkinsonism is not a common feature. A 
question  that  cannot  be  answered  in  this  thesis  is  whether  MIRAS patients  
would eventually have developed parkinsonism, if they had lived longer.  
7.2.2 POLG1-PD 
 
We studied here the neuropathology of the mesencephalon of two of the 
originally described POLG1-PD patients and other mtDNA maintenance 
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disorders patients (MIRAS, IOSCA and Twinkle-PEO) without signs of PD, to 
ask whether correlation in genotype and phenotype could be seen at the 
neuropathological level. We wanted to understand if parkinsonism is a 
feature caused by mutations in the catalytic domain of POLG1 or  do  other  
mutations, such as spacer mutations, also cause parkinsonism? Thus, we 
asked if neuropathological features could explain and verify the differences in 
the clinical phenotype of POLG1 and also Twinkle patients. 
 
The most drastic neuropathological finding in both patients was the 
almost complete destruction of the mesencephalon and especially SN and 
oculomotor  nucleus.  In  both  patients,  there  were  just  a  few  intact  pigment  
neurons  remaining  in  pars  compacta  of  SN.  In  the  oculomotor  nucleus  the  
destruction was not as complete, but still substantial. However, neither 
patient had Lewy-bodies in immunohistochemical stainings against p62, 
TAU or ?-synuclein. Both patients had moderate neuron loss in posterior 
spinocerebellar tracts, cerebellar cortex, dentate nucleus and inferior olives. 
The  thalamus  was  also  mildly  affected.  In  muscle  biopsy  samples  both  had  
typical findings for mitochondrial disease: COX negative fibers and mtDNA 
deletions. In comparison, we studied the mesencephalon in MIRAS, Twinkle 
PEO and IOSCA patients, who did not have parkinsonism. These patients 
had  moderate  (MIRAS,  Twinkle  PEO)  and  mild  (IOSCA)  loss  of  neurons  in  
pars compacta of SN and oculomotor nucleus and no signs of Lewy-bodies. 
 
Occasional dominant PEO-families have been reported with 
parkinsonism,  but  in  2004 these  cases  were  shown to  be  caused  by  POLG1  
mutations, indicating that POLG1 defects can cause parkinsonism (Chalmers 
et al., 1996; Checcarelli et al., 1994; Luoma et al., 2004; Moslemi et al., 1999; 
Siciliano  et  al.,  2001).  Not  all  POLG1  mutations  show  this  phenotype,  e.g.  
spacer mutations. Our POLG1-PD patients exhibit a similar phenotype as 
published cases of ARJPD: earlier onset of parkinsonian symptoms than in 
idiopathic PD, good response to levodopa treatment, no cognitive 
impairment  and  slow  progression  of  the  disease  course  (Albanese  et  al.,  
2005; Dekker et al., 2003; Ibáñez et al., 2006; Lücking et al., 2000; Mori et 
al., 1998; van de Warrenburg et al., 2001)..  
 
Neuropathological findings of ARJPD also resemble the changes seen in 
our patients: no Lewy-bodies, no ?-synuclein pathology and neuron loss 
limited to SN. In idiopathic PD, neuropathological changes also develop in 
other regions of the CNS than in mesencephalon [Reviewed in (Braak et al., 
2004)]. In fact, the first areas affected are not in mesencephalon, but in the 
dorsal motor nucleus of the vagal nerve from which the Lewy neurites branch 
into the Locus Coeruleus, Raphe nucleus and finally to the SN. When the first 
changes in the SN can be seen, the motor symptoms also develop. In the later 
course of idiopathic PD, changes develop widely in the CNS, for example, 
into the primary sensory and motor fields. The neuropathological changes in 
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idiopathic PD begin in limited areas and finally affect the whole brain. In 
ARJPD, this feature has not been reported and instead the patients have very 
limited loss of neurons in the SN. This progressing destruction was not seen 
in our patients: although our patients also had neuron loss in other parts of 
the  CNS,  they  did  not  exhibit  the  typical  PD  progression.  The  clinical  and  
neuropathological findings in POLG1-PD resemble ARJPD more than 
idiopathic PD and we consider POLG1-PD and ARJPD to be part of the same 
group, namely mitochondrial PD.  
 
Our initial hypothesis was that the mesencephalon and especially SN 
would  be  affected  only  in  patients  with  parkinsonism.  All  mtDNA  disorder  
patients examined had at least minor neuron loss in the SN. In oculomotor 
nucleus, the changes were not evident in every patient, as only Twinkle PEO 
and POLG1-PD patients had marked neuron loss in the oculomotor nucleus 
whereas IOSCA and MIRAS patients did not have any neuron loss in their 
oculomotor nucleus. In our patients the mitochondrial dysfunction is caused 
by a malfunction of mtDNA replication. In POLG1-PD, the defect is catalytic, 
whereas in MIRAS and IOSCA the catalytic activity of POLG or TWINKLE, 
respectively, is not affected (Hakonen et al., 2008a). In addition, MIRAS and 
IOSCA have tissue specific manifestations of mtDNA abnormalities, 
suggesting other regulating factors, which may affect the disease 
pathogenesis and ultimately the clinical phenotype. SN is a region of the 
brain, which is especially susceptible to even a small disruption in energy 
metabolism:  SN  neurons  are  distinct  from  other  neurons  in  that  they  have  
enormous terminal projection fields, directly influencing ~75000 striatal 
neurons. Their axons are long, thin and have a poor myelin sheath and they 
have  high  energy  expenditures  [Reviewed  in  (Braak  et  al.,  2004)].  Gene  
expression studies in rats suggest that energy metabolism transcripts are 
highly  expressed  in  the  SN,  supporting  the  view  that  the  SN  neurons  have  
high demands for energy metabolism and even a small disruption in this can 
lead to parkinsonism (Greene et al., 2005). However, the reason why only 
some patients with deficiency in mitochondrial DNA replication develop 
parkinsonism remains unknown. 
7.3 ANALYSIS OF RESPIRATORY CHAIN IN 
MESENCEPHALON (II) 
CI deficiency is a well-established feature in PD patients that has been 
described  in  multiple  tissues  and  can  be  described  as  a  widely  accepted  
starting hypothesis in PD research (Bindoff et al., 1989; Haas et al., 1995; 
Krige et al., 1992; Parker et al., 1989; Schapira et al., 1989; Yoshino et al., 
1992).  Also,  CI  inhibitors,  such  as  rotenone  and  MPTP cause  parkinsonism 
and can  be  used  to  produce  animal  models  for  PD.  In  addition,  MPP+,  the  
neurotoxic ion of MPTP, affects the mtDNA structure by destabilizing the D-
  63
loop structure, thus linking the neurotoxicity, mtDNA metabolism and 
parkinsonism (Miyako et al., 1999; Umeda et al., 2000). We wanted to study 
if  the  parkinsonism  in  POLG1-PD  patients  could  be  explained  by  a  
respiratory chain deficiency. We analysed the respiratory chain components 
by immunohistochemistry in the formalin fixed mesencephalon samples 
from patients: two POLG1-PD, three MIRAS, one IOSCA, one Twinkle-PEO 
patient and two healthy controls. All patients had a clear and dramatic 
decrease in CI immunoreactivity in the pigment neurons of SN (Figure 8). In 
the oculomotor nucleus, the decrease in CI immunoreactivity was evident in 
one  POLG1-PD,  MIRAS  and  Twinkle-PEO  patient.  The  lack  of  CI  
immunoreactivity did not correlate with the age of onset, phenotype or age of 
the  patients.  We  examined  if  the  CI  deficiency  was  associated  with  active  
proteolysis by analyzing the amount of a mitochondrial matrix-facing AAA-
protease, AFG3L2, in all patients. AFG3L2 immunoreactivity was present in 
the neurons of SN and oculomotor nucleus of all patients, with slightly more 
intense staining in MIRAS and POLG1-PD patients. No findings of 
respiratory chain deficiency in the mesencephalon have been reported 
previously in POLG1 or Twinkle patients, but we know that in MIRAS and 
IOSCA CI  deficiency   is  found in  the  neurons  of  the  cerebellum and frontal  
cortex  (Hakonen et  al.,  2008b).  In  a  recent  study  of  idiopathic  PD patients  
and single SN neurons, CI deficiency was however limited to SN neurons that 
did not have Lewy pathology (Reeve et al., 2012). Our results suggest that CI 
deficiency is a feature of disease caused by malfunction of mtDNA replication 
proteins, POLG or Twinkle, not a feature of POLG1-PD as such. Our results 
challenge the long-standing assumption that CI deficiency is causative for 
PD.  
 
Figure 8 Complex I in substantia nigra pigment neurons. Asterisk marks the normal pigment. 
A: POLG1-PD patient, a clear lack of complex I immunoreactivity (arrow). B: Healthy control. 
Normal complex I immunoreactivity in the neuron (arrow). NDUFS3 antibody. Brown: CI 
immunoreactivity, blue counterstaining. 
POLG-PD1 patients also had an increase in CII immunoreactivity in the 
SN pigment neurons, whereas MIRAS, IOSCA or Twinkle-PEO patients did 
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not have this change. The relevance of this increase remains unknown: CII 
might be upregulated as a protective mechanism in CI dysfunction. CII is the 
second entry point for electrons in the respiratory chain and increase in CII 
immunoreactivity raises the question whether substrates entering respiratory 
chain at CII are favored in these neurons. A reason for this might be that CI is 
a major ROS producer in mitochondria. If CI dysfunction leads to an increase 
in ROS production and thus mitochondrial stress, downregulation of CI and 
upregulation of CII might in fact be a protective factor against mitochondrial 
stressors. Another explanation is that CII is in this case a marker for 
mitochondrial quantity and increase in CII immunoreactivity tells us that the 
amount of mitochondria is increased as a compensatory mechanism.  
 
We also examined the immunoreactivity against CIII and CIV. None of 
our patients had any changes in CIII or CIV immunoreactivity, in SN or 
oculomotor nucleus.  
7.4 FUNCTIONAL AND STRUCTURAL ANALYSIS OF 
P.TRP748SER POLG1 (III) 
MIRAS is caused by two nucleotide changes in POLG1: c.2243G?C in cis 
with c.3428A?G, resulting in p.Trp748Ser + p.Glu1143Gly amino acid 
changes. C.2243G?C is a disease causing mutation, whereas c.3428A?G is 
considered  to  be  a  polymorphism,  with  a  frequency  of  ~3%  in  the  general  
Finnish population. Previous work in our lab has showed that c.2243G?C in 
cis with c.3428A?G  allele  arose  from  a  common  European  founder  
(Hakonen et al., 2007a; Hakonen et al., 2005). The clinical manifestations of 
MIRAS are severe, but the disease itself shows great heterogeneity in age of 
onset and other features. MIRAS mutations are also a known cause of Alpers’ 
disease, widening the clinical spectrum even more. We wanted to study the 
biochemical  phenotype  of  p.Trp748Ser  in  POLG1,  to  understand  why  this  
amino acid change is associated with so many phenotypes and produces 
variable clinical manifestations. We produced the recombinant mutant 
enzyme using a baculovirus expression system. We purified in total two 
exonuclease deficient proteins: wild-type and p.Trp748Ser POLG1. The 
exonuclease  activity  was  eliminated  by  two  amino  acid  substitutions  in  the  
exonuclease domain of POLG1, as described previously (Longley et al., 
1998a).  Exonuclease  deficient  POLG1  was  used,  as  we  knew  from  previous  
studies that the exonuclease activity of POLG1 might mask a deficiency in 
DNA polymerase activity (Graziewicz et al., 2004). Both enzymes were 
purified twice, in independent purifications, 180-fold with a final yield of 6%. 
All protein preparations were of similar purity and we did not find any signs 
of structural instability in any purified protein.  
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Table 4. Catalytic properties of mutant POLG1 enzymes. p.Trp748Ser vs wild type 
POLG1, data in last column adapted from (Chan et al., 2006) 
 Wild type 
POLG1 
p.Trp748Ser 
POLG1 
p.Ala467Thr 
POLG1 
p.Trp748Ser 
vs wild type 
POLG1, 
(Chan et al.) 
Specific activity (units/ 
mg)  
    
Gapped double-stranded 
DNA 
8100- 9300 7200- 26 000 3900 - 
Poly (rA)- oligo (dT) 712 ± 121 852 ± 209 - 2.3% 
Singly-primed M13 DNA 123 ± 14 143 ± 17 - - 
Km (µM dNTP)      
Gapped double-stranded 
DNA 
66.1 ± 6.3 66.5 ± 4.8 - - 
Singly-primed M13 DNA 0.77 ± 0.07 0.75 ± 0.06 - - 
Poly (rA)- oligo (dT) - - - 6 % 
Average processive unit 
(nt)  
    
POLG1 52.8 ± 13.6 48.2 ± 12.7 55.8 ± 13.4 - 
POLG holoenzyme 245 ± 34.0 257 ± 32.8 144 ±26.9 - 
DNA binding affinity, 
Kd (nM)  
6.8 ± 0.37 11.1 ± 0.52 - - 
DNA binding affinity, 
catalytic core 
- - - 8-fold decrease 
 
 
We did our initial analysis of DNA polymerase activity using gapped, 
natural sequence dsDNA as a template. We used a third, previously purified 
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and published p. Ala467Thr POLG1 mutant enzyme as a control for a 
catalytic defect (Luoma et al., 2005). We measured the specific activities to 
be  8100-9335  U/mg,  7200-26000  U/mg  and  3900  U/mg,  for  wild-type,  
p.Trp748Ser and p. Ala467Thr respectively (Table 4). As this initial analysis 
revealed normal p.Trp748Ser DNA polymerase activity and we were able to 
replicate the previously published catalytic defect of p. Ala467Thr POLG1, we 
wanted to study the processive DNA polymerase activity next. We know from 
previous work, that POLG1 is able to use various ptDNAs and the activity of 
the enzyme is higher with templates with high primer density. To understand 
if  p.Trp748Ser  POLG1  DNA  polymerase  activity  would  be  diminished  with  
more challenging ptDNA, we used two different primer templates: singly-
primed, natural sequence M13 DNA and multi-primed, artificial sequence 
poly (rA)·oligo(dT). For M13 DNA, the specific activities were 123 ± 14 and 
143  ±  17  U/mg  for  wild-type  and  p.Trp748Ser  POLG1.  For  poly  
(rA)·oligo(dT), the specific activities were 712 ± 121 and 852 ± 209 U/mg, 
respectively. The analysis of DNA product strand lengths with denaturing gel 
electrophoresis confirmed our results from different primer-templates: wild-
type  POLG1  had  an  average  processed  unit  (APU)  of  52.8  ±  13.6  nt,  
p.Trp748Ser POLG1 48.2 ± 12.7 nt and p. Ala467Thr POLG1 55.8 ± 13.4 nt. 
The steady state kinetics of the catalytic core, on gapped, natural sequence 
DNA did not reveal any significant differences: the Km values were 66.1 ± 6.3 
and 66.5 ± 4.8 µM dNTP for wild-type and p.Trp748Ser POLG1. In 
conclusion,  we  studied  the  DNA polymerase  activity  of  p.Trp748Ser  POLG1  
using  multiple  templates  and  tests.  None  of  them  revealed  any  decrease  in  
the DNA polymerase activity of the p.Trp748Ser POLG1. The lack of a DNA 
polymerase defect can question the possible pathogenicity of p.Trp748Ser 
POLG1, but we have previously published two other disease-related spacer 
mutants,  p.  Arg627Gln,  p.  Arg627Trp,  which  did  not  exhibit  a  biochemical  
phenotype. Also, the MIRAS disease allele is not found as a homozygote in 
healthy controls. The lack of catalytic deficiency is not a specific feature of 
MIRAS:  in  IOSCA,  the  disease  causing  mutation  in  Twinkle  does  not  affect  
the catalytic activity of the TWINKLE helicase (Hakonen et al., 2008a).  
 
In previous biochemical characterizations of the POLG1 spacer region 
mutant, p. Ala467Thr, both Luoma and co-workers and Chan and co-workers 
reported a remarkable decrease in polymerase activity and interaction with 
the accessory subunit,  POLG2 (Chan et  al.,  2005; Luoma et  al.,  2005).  This 
prompted us to study the function of the POLG holoenzyme. The holoenzyme 
was reconstituted with the same POLG1 enzymes as in other assays and four-
fold molar excess of POLG2 accessory subunit, with optimal reaction 
conditions for holoenzyme. Again, we used M13 DNA for the initial analysis 
of steady state kinetics. Both wild-type and p.Trp748Ser POLG holoenzyme 
had  similar  Km values:  0.77  ±  0.07  and  0.75  ±  0.06  µM  dNTP.  Next,  we  
measured the DNA binding capability of the holoenzyme with quantitative 
electrophoretic  mobility-shift  with  a  21/45-mer  DNA  as  a  primer-template.  
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The  reconstituted  wild-type  POLG  holoenzyme  had  a  Kd  of  6.8  ±  0.37  nM  
whereas p.Trp748Ser POLG holoenzyme had a slightly lower affinity, 11.1 ± 
0.52 nM. The biochemical characterization of p.Trp748Ser POLG1 was 
completed with the measurement of the processivity of the holoenzyme. 
There was no significant change in the average processed units (APU): 245 ± 
34.0,  257  ±  32.8  and  144  ±26.9  nt  for  wild  type,  p.Trp748Ser  and  p.  
Ala467Thr POLG holoenzyme, respectively. The holoenzyme processivity was 
~5 fold higher than the catalytic core alone with wild-type and p.Trp748Ser 
POLG holoenzyme, whereas p. Ala467Thr POLG1, with a known defect in 
subunit interaction, was stimulated only ~2.6 fold when compared to the 
processivity of the catalytic core alone. We can conclude that the subunit 
interaction of p.Trp748Ser POLG1 was not affected and cannot explain the 
clinical phenotype. 
 
The recently published crystal structure of human POLG1 enabled us to 
study the location of p.Trp748 and p.Glu1143 amino acids on the tertiary 
structure of POLG1 and explain the lack of biochemical phenotype in our 
assays (Lee et al., 2009). The p.Trp748  amino acid maps to a cluster on the 
tertiary structure of POLG1 that does not take part in DNA synthesis, but is 
predicted to affect the interaction with other mtDNA replication proteins, 
mtSSB (Figure  9).  Two other  Alpers’  disease  amino  acid  changes,  which  do  
not  cause  a  biochemical  phenotype,  are  also  located  in  this  cluster:  p.  
Arg627Trp/Gln. To date, no biochemical defect has been reported in the 
interaction of human POLG and mtSSB, caused by POLG1 amino acid 
changes. However, human mtSSB amino acid changes lead to diminished 
POLG stimulation (Oliveira and Kaguni, 2010; Oliveira and Kaguni, 2011). 
Chan and co-workers have published a biochemical study of p.Trp748Ser, 
p.Glu1143Gly  and  p.Trp748Ser  +  p.Glu1143Gly  POLG1  (Chan  et  al.,  2006).  
They reported a severe DNA polymerase defect in p.Trp748Ser POLG1, which 
was partially rescued by the p.Glu1143Gly amino acid change. Their data 
suggested that the deficiency was caused by a weakened DNA binding 
capability of p.Trp748Ser POLG1. However, based on our careful biochemical 
analysis  of  p.Trp748Ser  POLG1  and  analysis  of  POLG1  crystal  structure  we  
conclude that p.Trp748Ser POLG1 does not affect the intrinsic DNA 
polymerase or DNA binding ability and the defect reported by Chan and co-
workers is most likely artefactual. 
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Figure 9 Location of p. Glu1143 and p. Trp748 amino acids in  POLG1. Blue double strand: 
primer-template DNA. p. Trp748 and p. Glu1143 amino acids are located in different parts of 
the POLG1 enzyme and neither of them is involved directly in DNA binding. 
  
The role of the putative polymorphism c. 3428A?G, leading to amino 
acid change p.Glu1143Gly in POLG1 has been unclear. The structural data 
shows that p.Glu1143 amino acid maps near amino acids that are located in 
the pol domain of POLG1 (Figure 10). However, this amino acid is located at 
the outer edge of the enzyme, not in the vicinity of the pol site. Defects in this 
structure are predicted to reduce the polymerase rate of POLG1, based on 
their distances from the pol active site (Kasiviswanathan et al., 2009). 
Secondly,  p.Glu1143  is  in  a  different  part  of  the  POLG1  enzyme  than  
p.Trp748Ser.  The  distance  between  these  amino  acids  is  ~61.5  Å.  In  yeast,  
the equivalent amino acid change leads to a decrease in  polymerase activity, 
due to structural instability of the POLG1 enzyme (Baruffini et al., 2007).  We 
find it improbable that it would affect the DNA polymerase activity, let alone 
rescue a possible defect caused by an amino acid change in a different part of 
the enzyme. The p. Gln1236His amino acid change, caused by c. 3708 G?T 
mutation in POLG1, also leads to an increase in POLG1 function. p. 
Gln1236His is thought to be a polymorphism and is found in cis with the p. 
Arg627Gln  amino  acid  change  (Luoma et  al.,  2005).  Although it  is  possible  
that these polymorphisms give the mutant enzyme an evolutionary advance 
over single amino acid changes, we find it highly unlikely that they would 
rescue an enzyme lacking nearly all activity. 
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Figure 10 Relationship of p. Glu1143 and the pol active site. Blue double strand: DNA. Pink 
sheets: Beta-sheets. Tyr955 is located in the pol active site. Glu1143 is the most lateral 
amino acid in the structure formed by the three beta sheets. Mutations in these beta-sheets 
result in the reduction of DNA polymerase activity, but the long distance between Glu1143 
and pol active site make it unlikely that Glu1143 would affect the polymerase activity of the 
enzyme in increasing manner. 
7.5 OVEREXPRESSION OF C.2243G?C MUTANT 
POLG1 IN CELLS (III) 
We created a cell-based, retroviral overexpression system to be used as a 
modelling tool to study the effect of the POLG1 c.2243G?C, c.3428A?G and 
c.2243G?C in cis with c.3428A?G  mutants.  We  achieved  a  high  level  of  
POLG1 overexpression in primary cells with all retroviral vectors: with 
quantitative  RT-PCR,  the  overexpression  was  7-19  fold  higher,  when  
compared to endogenous expression levels. We also measured the expression 
level of Twinkle and  found  no  change.   Neither  mtDNA  levels  nor  
mitochondrial translation were affected by the overexpression of wild type or 
mutant POLG1. Although this system worked properly, we were unable to use 
it in the analysis of the mutations, due to the lack of downstream changes. 
This was probably due to the remaining endogenous wildtype POLG, which 
was likely able to compensate the functional defect caused by recessive 
p.Trp748Ser POLG. The same phenomenon has been described also for 
another recessive POLG1 amino acid change, p. Gly848Ser (Atanassova et al., 
2011). 
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7.6 CLUSTERING OF ALPERS’ DISEASE MUTATIONS IN 
POLG1  (III,  IV) 
Alpers’ disease is a recessive disease, caused by multiple different compound 
heterozygous or homozygous mutations in POLG1 or Twinkle (Naviaux and 
Nguyen, 2004; Sarzi et al., 2007). The large number of known causative 
mutations for Alpers’ disease and other diseases caused by POLG1 mutations 
makes it difficult to analyse the biochemical deficiency manually, as the 
characterization of each different mutant enzyme requires construction and 
purification of altered protein, which is both a time consuming and error 
prone operation. In addition, the standard measurement of DNA polymerase 
activity, processivity, DNA binding affinity and interaction with POLG2 does 
not necessarily  exhibit  a  clear biochemical  phenotype,  as is  the case with p.  
Trp748Ser amino acid change. Also, cell culture based systems cannot be 
used reliably in the analysis of POLG activity because of our inability to block 
the activity of other DNA polymerases reliably. Thus, we wanted to produce a 
robust  tool  to  examine  the  possible  pathogenicity  of  the  current  and  new  
mutations in the POLG1. Utilizing the three dimensional model of POLG, 
based on the crystallization of the protein, we examined the crystal structure 
of  human POLG in  its  apoenzyme form (Lee  et  al.,  2009).  We also  utilized  
and combined the biochemical data accumulated during the last decades 
from D. melanogaster, S. Cerevisiae and human mutations with the 
published crystal structure of POLG. This extensive combination of data 
indicated that the mutations in linear DNA and protein structures of POLG1 
cluster  within  the  tertiary  structure  to  five  distinct  clusters,  despite  no  
apparent clustering to previously known protein clusters having been seen.  
 
 
Cluster 1 residues affect the polymerase activity either via pol active site, 
DNA binding channel or the surrounding architecture. POLG1 p. Tyr955Cys 
amino acid change causes adPEO with parkinsonism, with multiple mtDNA 
deletions  (Figure  5)  (Van  Goethem et  al.,  2001).  This  change  locates  to  the  
pol active site (Figure 10). The biochemical phenotype caused by this amino 
acid change is dramatic: almost complete lack of the polymerase activity, 
error-prone DNA synthesis and sensitivity to dNTP concentration 
(Graziewicz et al., 2004; Ponamarev et al., 2002). The multiple mtDNA 
deletions are explained by sensitivity to dATPs: in low dATP concentration p. 
Tyr955Cys POLG1 exhibits stalling phenotype at dATP insertion sites 
(Atanassova et al., 2011). Other amino acid changes in this cluster do not 
necessarily exhibit as clear biochemical phenotype. For example, p. 
Thr885Ser amino acid change, which causes Alpers’ disease, is located near 
the pol active site, in the adjacent beta-sheets. This change reduces the DNA 
polymerase activity two-fold. Other changes in the same beta-sheet structure 
reduce also DNA polymerase activity, with the reduction being more severe 
the  closer  the  change  is  to  pol  active  site  (Kasiviswanathan  et  al.,  2009).  
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These two changes underline the different biochemical and clinical 
phenotypes caused by changes in the same functional domain of POLG.  
 
Cluster 2 is composed of residues that interact with the upstream DNA 
duplex.  These  residues  are  part  of  the  spacer  domain.  The  p.  Ala467Thr  is  
probably the most common disease-causing amino acid change in POLG1 
and  is predicted to locate within cluster 2 (Figure 5). In D. melanogaster, a 
triple change of amino acids p. Pro556Ala, p. Lys557Ala and p. Ile558Ala 
disrupts a hydrophobic structure, which shapes the DNA binding channel 
wall and leads to a complete lack of DNA binding and DNA polymerase 
activity (Luo and Kaguni, 2005). The amino acid change p. Ala467Thr in 
human POLG1 disrupts the same structure and also leads to a decrease in 
DNA binding and DNA polymerase activity, which is partially rescued by 
POLG2 (Chan et al., 2005; Luoma et al., 2005). These results are in line with 
the structural data, implying that the residues in this cluster affect the DNA 
polymerase activity due to changes in the DNA binding channel, and 
decreased  processivity  due  to  inability  of  accessory  subunit  to  stabilize  the  
DNA binding channel.  
 
Cluster 3 residues form a structure for which we proposed the name 
“partitioning loop”. Mutations in cluster 3 residues, for example the p. 
Leu304Arg, cause PEO, SANDO and Alpers’ disease (Figure 5) (Tang et al., 
2011). In yeast, the equivalent amino acid changes cause lack of processive 
DNA polymerase activity, low DNA binding affinity and increased 3’-5’ 
exonuclease activity (Szczepanowska and Foury, 2010). These biochemical 
properties are explained by the structural data: the partitioning loop is 
proposed to modulate the partitioning of the primer strand between the pol 
and exo active sites. ptDNA that contains mispairs or lesions is destabilized 
and then led to a exo active site, whereas correctly paired ptDNA is stabilized. 
Malfunction of partitioning affects the exonuclease activity, thus explaining 
the biochemical phenotype of p. Leu304Arg POLG1.  
 
Cluster 4 can be defined as residues around the residue p. Arg232, which 
affects the interaction with the distal POLG2. POLG1 mutations leading to 
amino acid changes p. Arg232Gly and p. Arg232His cause Alpers’ disease, 
which is explained by the biochemical phenotype of mutant enzymes: 
decreased DNA polymerase activity, DNA binding and disruption of 
exonuclease activity (Figure 5) (Ashley et al., 2008; Ferrari et al., 2005; Lee 
et al., 2010a).  Structural data shows that the interaction between POLG1 and 
the  distal  accessory  subunit  is  through  one  ion  bond:  this  bond  is  between  
POLG1 p. Arg232 and POLG2 p. Glu394. Overall the distal accessory subunit 
increases the polymerization rate of the holoenzyme (Lee et al., 2010b). 
Thus, cluster 4 mutants affect the interaction between POLG1 and the distal 
POLG2. 
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Cluster  5 is located in the distal surface of the IP subdomain, distant 
from the DNA binding channel. Several important amino acid changes, 
leading to clinical phenotypes, map to this cluster: p.Trp748Ser, leading to 
MIRAS, p. Arg627Trp/Gln leading to Alpers’ disease and others (Figure 5). 
The biochemical data from D. melanogaster support  a  disruption  in  the  
interaction between the POLG holoenzyme and mtSSB (Luo and Kaguni, 
2005). The data also support the finding that residues in cluster 5 do not lead 
to a catalytic defect (Luoma et al., 2005). 
 
Clustering of the Alpers’ syndrome-causing mutations enabled us to ask 
what kinds of mutation combinations are allowed in compound heterozygous 
situations in Alpers’ disease patients. One important finding in our study was 
that the compound heterozygous mutations map to different clusters. The 
conclusion from this is that although a single, recessive mutation as a 
homozygous mutation may cause a mild or non-existent biochemical 
phenotype, a combination of two alterations in different clusters of POLG1 
leads to stronger clinical phenotype (Naviaux and Nguyen, 2004). Also, two 
different mutations in a single cluster would predictably lead to a drastic 
biochemical phenotype. However, no such combinations are reported in the 
literature, which suggest that such combinations are not tolerated. POLG 
holoenzyme is a heterotrimer, but we do not know if two holoenzymes work 
together, both replicating different strands of mtDNA. This would explain the 
more severe clinical picture of compound heterozygous mutations. A recent 
characterization of p. Tyr955Cys POLG1 examined the dominant effect of the 
mutations and found that  in the presence of  wild type POLG1 only a minor 
amount of full-length replication products are produced, due to the stalling 
of replication with p. Tyr955Cys POLG1, whereas with recessive p. Gly848Ser 
the addition of wild-type POLG1 rescues the phenotype (Atanassova et al., 
2011). This result can be extrapolated to explain the more drastic phenotype 
of compound heterozygous mutations: no wild-type POLG1 exists and both 
mutant POLG1 enzymes accelerate the deficiency of POLG1 function via 
different mechanisms. 
 
Currently, analysis of POLG1 mutations is troublesome: the mutations 
cause different phenotypes and no reliable way to predict the possible 
pathogenicity or biochemical phenotype exists. At present, the pathogenicity 
of  a  new  mutation  is  predicted  by  studying  the  possible  absence  in  the  
normal population, conservation of the affected amino acid among species 
and segregation in the patient’s family. The prediction tool that we have 
created, utilizing the 3D POLG1 structure and functional domain data, may 
aid clinicians in predicting the possible effect and pathogenicity of a new 
disease variant. 
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8 CONCLUSIONS AND FUTURE 
PROSPECTS 
The  work  presented  in  this  thesis  provides  new  information  about  the  
pathogenesis and clinical manifestations of POLG disorders. We have found 
that all examined patients with an mtDNA replication disorder have 
neuronal  loss  in  the  SN  and  most  importantly,  that  CI  deficiency  does  not  
explain the parkinsonism in the POLG1-PD patients. Our results give insight 
into the clinical variety of POLG1 manifestations, based on the biochemical 
characterization of MIRAS POLG1 and structural analysis of POLG1 
holoenzyme. Structural analysis of POLG holoenzyme and Alpers’ disease 
mutations reveal new functional domains in the POLG structure, which may 
aid the clinician in the evaluation of new POLG1 mutations.  
 
In countries with a high carrier frequency of the MIRAS disease allele, a 
family  history  suggesting  dominant  inheritance  should  not  be  an  exclusion  
criterion for a MIRAS diagnosis. We described a family in which both the 
mother and son had MIRAS, mimicking dominant spinocerebellar ataxia. 
The high carrier frequency of the disease allele had caused two separate 
introductions of the disease allele in the family and hence masked the 
recessive inheritance pattern.  
 
CI deficiency of SN neurons was not the primary cause of parkinsonism in 
POLG1-PD  patients,  as  we  saw  the  same  level  of  CI  deficiency  in  MIRAS,  
IOSCA and Twinkle PEO patients, without correlation to age, age of onset or 
clinical phenotype of the patients. The neuron loss in SN correlated well with 
parkinsonism:  POLG1-PD patients  had  an  almost  complete  lack  of  neurons  
in  the  SN  whereas  MIRAS,  IOSCA  and  Twinkle  PEO  patients,  who  did  not  
have  parkinsonism,  had  mild  to  moderate  neuron  loss  in  the  SN.  In  our  
opinion neuronal CI deficiency is a general feature of the diseases caused by 
malfunction of the mtDNA replication machinery and whether it contributes 
to pathogenesis or is a physiological response remains to be studied. We do 
not, however, understand what causes the tissue specific changes, or why 
Twinkle and POLG1 disease have such heterogeneity in their symptoms and 
disease progression. Patients with PEO and parkinsonism, caused by Twinkle 
mutations have been described in the literature, but no neuropathological 
examinations exist. This would help to understand the variability in the 
manifestation of parkinsonism in PEO patients. Also, no animal models of 
POLG1-PD, MIRAS or IOSCA exist currently and to understand the tissue 
specific changes and disease progression, an animal model would be an ideal 
tool. 
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Our structural analysis of POLG1 suggests that p.Trp748Ser, a common 
cause for MIRAS, participates in the interaction with mtSSB or Twinkle, and 
may thus affect  the function of  mtDNA replisome. This is  supported by our 
biochemical characterization of p.Trp748Ser in POLG1, in which we did not 
see a direct effect on the catalytic activity or subunit interaction of POLG. 
Alteration in this interaction could lead to malfunction of mtDNA replication 
machinery. This hypothesis needs further investigation. 
 
Recessive mutations in POLG1 map into five clusters on the tertiary 
structure of POLG1. The functional profile of each cluster is predicted to be 
distinct: this is supported by the structural analysis and biochemical profiles 
of examined mutant proteins. We learned that in patients with compound 
heterozygous changes in POLG1 the changes seem to map to different 
clusters  and  the  lack  of  two  different  changes  in  the  same  cluster  would  
suggest that such a combination would not be tolerated. Homozygous 
changes, such as p. Ala467Thr are an exception to this. However, patients 
with homozygous changes in POLG1 seem to have less severe clinical 
manifestation than patients with compound heterozygous changes, as is the 
case in MIRAS and Alpers’ disease. This suggests that for an unknown reason 
the homozygous changes are tolerated more. Using the structural data and 
information about the clusters, clinicians might be able to predict the 
possible consequences of a new mutation. This is valuable, as the number of 
known POLG1 mutations is increasing constantly and doing an individual 
functional assessment of each POLG1 mutation is time consuming and error 
prone.  
 
The current advances in sequencing techniques, such as whole-exome and 
whole genome sequencing have already provided us with multiple new 
disease loci for mtDNA replication diseases. This development will continue 
and most likely will be the basis for mitochondrial research for the next few 
years. It will not, however, provide us with the understanding of what causes 
the clinical heterogeneity of POLG1 or mtDNA replication disease in general. 
We know the basic mtDNA replication machine well and we understand how 
the  individual  components  work.  Despite  this,  we  do  not  know  how  all  the  
components function together. One explanation for the clinical heterogeneity 
is  disruption  in  the  function  of  the  whole  mtDNA replisome:  the  structural  
data suggests an interaction with POLG and mtSSB, which might be the 
disease causing disruption in MIRAS. The challenge is to understand the 
function of the whole mtDNA replication system and the factors affecting it, 
not just individual components. Maybe then we will have the ability to 
understand the varying clinical phenotypes.  
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